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Abstract
Humane care for critically ill pediatric patients supported on mechanical ventilation necessitates comfort
management that includes sedation therapy. Critically ill patients quickly become tolerant to the opioids
and benzodiazepines used for sedation therapy and require increasing doses of these medications to
achieve the same therapeutic effect. In turn, after recovery from their primary illnesses, rapid weaning or
abrupt cessation of sedative therapy in drug tolerant patients precipitates iatrogenic withdrawal
syndrome - a problem that adds to the personal and financial burden of intensive care. While numerous
studies have focused on illuminating iatrogenic withdrawal syndrome symptomatology, a new perspective
for addressing this preventable complication of pediatric intensive care is now warranted. This
dissertation will use data from the RESTORE clinical trial [U01HL086622 and U01HL086649 (PI: Curley &
Wypij); 31-center cluster randomized trial of nurse-led sedation management on clinical outcomes in
children requiring mechanical ventilation for acute respiratory failure] to conduct a series of analyses
comparing patient-, process- and system-level data between those subjects who developed iatrogenic
withdrawal syndrome and those who did not. By exploring variables at multiple levels, this study will be
the most comprehensive evaluation of iatrogenic withdrawal syndrome ever completed and will
contribute new knowledge to the field. The studies will collectively answer the key question: What factors
impact the development of iatrogenic withdrawal syndrome in pediatric patients recovering from critical
illness? Furthermore, the relative contributions of patient, process, and systems factors will be combined
to create a predictive model of patient risk for clinically significant iatrogenic withdrawal syndrome in
pediatric patients recovering from critical illness. This dissertation will contextualize the phenomenon of
iatrogenic withdrawal syndrome within the unique clinical circumstances in which it occurs. More
importantly, risk factors identified through this study could lead to the development of personalized risk
profiles and prevention protocols for vulnerable children in the pediatric intensive care unit.
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ABSTRACT
DEFINING RISK FOR IATROGENIC WITHDRAWAL IN
CRITICALLY ILL CHILDREN
Kaitlin M. Best
Martha A. Q. Curley
Humane care for critically ill pediatric patients supported on mechanical ventilation
necessitates comfort management that includes sedation therapy. Critically ill patients
quickly become tolerant to the opioids and benzodiazepines used for sedation therapy and
require increasing doses of these medications to achieve the same therapeutic effect. In
turn, after recovery from their primary illnesses, rapid weaning or abrupt cessation of
sedative therapy in drug tolerant patients precipitates iatrogenic withdrawal syndrome - a
problem that adds to the personal and financial burden of intensive care. While numerous
studies have focused on illuminating iatrogenic withdrawal syndrome symptomatology, a
new perspective for addressing this preventable complication of pediatric intensive care
is now warranted. This dissertation will use data from the RESTORE clinical trial
[U01HL086622 and U01 HL086649 (PI: Curley & Wypij); 31-center cluster randomized
trial of nurse-led sedation management on clinical outcomes in children requiring
mechanical ventilation for acute respiratory failure] to conduct a series of analyses
comparing patient-, process- and system-level data between those subjects who
developed iatrogenic withdrawal syndrome and those who did not. By exploring variables
at multiple levels, this study will be the most comprehensive evaluation of iatrogenic
withdrawal syndrome ever completed and will contribute new knowledge to the field.
v

The studies will collectively answer the key question: What factors impact the
development of iatrogenic withdrawal syndrome in pediatric patients recovering from
critical illness? Furthermore, the relative contributions of patient, process, and systems
factors will be combined to create a predictive model of patient risk for clinically
significant iatrogenic withdrawal syndrome in pediatric patients recovering from critical
illness. This dissertation will contextualize the phenomenon of iatrogenic withdrawal
syndrome within the unique clinical circumstances in which it occurs. More importantly,
risk factors identified through this study could lead to the development of personalized
risk profiles and prevention protocols for vulnerable children in the pediatric intensive
care unit.
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CHAPTER 1
INTRODUCTION
The rapid evolution of pediatric intensive care over the past 40 years has been
accompanied by fundamental changes in comfort management for critically ill children.
Comfort care in critically ill, non-surgical pediatric patients supported on mechanical
ventilation relies primarily on the use of opioids and benzodiazepines for sedation. However,
tolerance to and physical dependence on the opioids and benzodiazepines used for
sedation therapy can develop within a short span of time (Anand et al., 2010; Barr,
McPhie-Lalmansingh, Perez, & Riley, 2011; Jenkins, 2011). During recovery from their
primary illnesses, failure to gradually wean sedative therapy in physically dependent
patients leads to iatrogenic withdrawal syndrome (IWS), a cluster of physiologic signs
and symptoms that includes elevated temperature, tachycardia and hypertension,
protracted vomiting, severe diarrhea, and seizures (Franck, Harris, Soetenga, Amling, &
Curley, 2008; Franck, Scoppettuolo, Wypij, & Curley, 2012). Despite this known
complication of sedation therapy, opioids and benzodiazepines are an essential
pharmacologic therapy in the pediatric intensive care unit (PICU); therefore, this
dissertation study explores risk factors for IWS in critically ill children, in order to further
our understanding of which children are at greatest risk for experiencing this
phenomenon and arm clinicians with knowledge on how best to prevent IWS.
This chapter will provide important background information regarding the clinical
circumstances in which critically ill children receive PICU care and experience the use of
sedative and analgesic medications, in order to provide a more complete understanding of
the context in which the phenomenon of IWS occurs. Subsequent chapters will present
1

the three component papers that comprise this dissertation study: First, a systematic
review of the available literature was undertaken in order to identify known risk factors
for IWS (Chapter 2). Established and hypothesized risk factors were incorporated into a
conceptual model that guided subsequent data analyses. The remaining sections of this
dissertation study used data from the Randomized Evaluation of Sedation Titration fOr
Respiratory FailurE (RESTORE) study (U01HL086622 and U01 HL086649; PIs: Curley
& Wypij), a 31-center cluster randomized trial investigating the effects of a nurse-led,
goal-directed sedation management protocol on clinical outcomes in children requiring
mechanical ventilation for acute respiratory failure in the PICU.
Given the key role that the rate of sedation weaning plays in the incidence of
IWS, the second component of this study analyzed current patterns of weaning from
sedative medications in usual practice, using data from 308 subjects enrolled during the
baseline, pre-randomization phase of the RESTORE trial (Chapter 3). The findings from
that analysis helped elucidate the relationships among tolerance, weaning, and IWS.
Specifically, analysis of the baseline population allowed development, testing and
refinement of operational definitions for tolerance and weaning that were under
developed in the literature on IWS in the PICU; those definitions and identified
relationships between tolerance and pattern of weaning offered important insights
affecting the incorporation of those variables in later analyses.
Finally, a secondary analysis of existing data from the 2449 subjects enrolled
during the intervention phase of the RESTORE trial was conducted, in order to identify
statistically significant risk factors associated with the outcome of IWS (Chapter 4). By
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exploring variables at several levels, this study is one of the most comprehensive
evaluations of IWS to date.
	
  

The specific aims for this dissertation were as follows:
1. To identify risk factors for clinically significant IWS in pediatric patients
recovering from critical illness. (CHAPTER 2)
2. To characterize patterns of weaning from opioids and/or benzodiazepines in
pediatric patients recovering from critical illness, as they relate to the outcome of
clinically significant IWS. (CHAPTER 3)
3. To create a predictive model of patient risk for clinically significant IWS in
pediatric patients recovering from critical illness, based on the relative
contributions of patient, process, and systems factors. (CHAPTER 4)

The following sections provide a comprehensive discussion of the population of patients
who require sedation in the PICU, the context in which sedative medications are
administered, and how these factors contribute to the development of IWS. The
biological mechanisms underlying the development of tolerance, physical dependence
and subsequent IWS are described. In addition, current clinical practices in assessing for
and managing IWS are reviewed. This information provides the necessary baseline
knowledge upon which the three studies in the remainder of the dissertation were built.
Background
Nearly 150,000 critically ill infants and children in the United States are
supported on invasive mechanical ventilation in the PICU every year (Agency for
Healthcare Quality and Research, 2009). Various ventilator modes have been developed
3

to attempt to match ventilator-delivered breaths with the child’s spontaneous efforts, but
patient-ventilator asynchrony still develops and can be a source of significant discomfort
(Cheifetz, 2003). Humane care for these patients necessitates comfort management, a
multi-dimensional concept that addresses issues of pain, agitation, anxiety, and insomnia.
Approaches to care include both non-pharmacologic and pharmacologic interventions to
increase patient comfort (Anand & the International Evidence-Based Group for Neonatal
Pain, 2001; Herr et al., 2006). Because of the diversity of pharmacologic agents available
for comfort management, by the time the first consensus guideline on sedation
management in critically ill children was released in the United Kingdom in 2006,
(Stephen Playfor et al., 2006) up to 24 different medications were being used in PICUs
worldwide for analgesia and sedation to facilitate mechanical ventilation (Jenkins,
Playfor, Bevan, Davies, & Wolf, 2007; Twite, Rashid, Zuk, & Friesen, 2004; Vet et al.,
2013).
Combination therapy, including an opioid and a benzodiazepine, is the most
common strategy for sedation of patients in the PICU (Ista, van Dijk, Gamel, Tibboel, &
de Hoog, 2008; Jenkins et al., 2007; Vet et al., 2013). The recommended and most
commonly used medications are morphine, fentanyl and midazolam (Jenkins et al., 2007;
Lasky, Ernst, & Greenspan, 2012; Twite et al., 2004). Continuous infusions of opioids,
including morphine and fentanyl, have rapid analgesic effects that are useful in reducing
discomfort associated with mechanical ventilation, while also helping to prevent
ventilator asynchrony and working synergistically with benzodiazepines to promote
sedation (Johnson, Miller, & Hagemann, 2012). Benzodiazepines are highly effective
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sedatives and anxiolytics, and their amnestic effects are also valued in the PICU, where
memories of mechanical ventilation and invasive procedures can have significant, longterm negative psychological effects (Colville, Kerry, & Pierce, 2008; Colville, 2008;
Rennick & Rashotte, 2009; Rennick et al., 2004).
Context of Sedation Management in the PICU
Sedation for mechanical ventilation in the PICU takes place within a unique
context, whose characteristics both directly and indirectly impact the effectiveness of the
therapies that are delivered. A number of factors have been found to influence nurses’
provision of sedation therapy in the adult ICU literature, including: lack of standing
physician orders, lack of acceptance for sedation protocols (Tanios, de Wit, Epstein, &
Devlin, 2009), nurses’ knowledge and attitudes, and perceived autonomy in managing
sedative administration (Guttormson, Chlan, Weinert, & Savik, 2010). These findings can
reasonably be extrapolated to the population of pediatric critical care nurses. Other
literature has shown that nurses’ level of education and clinical experience (Aiken,
Clarke, Cheung, Sloane, & Silber, 2003; Coffman et al., 1997; Kutney-Lee, Sloane, &
Aiken, 2013) influence their ability to manage patient complications and provide comfort
care during acute illness. Less experienced nurses are more likely to administer sedatives,
preferring more sedated patients (Egerod, 2002; Guttormson et al., 2010). By contrast,
more experienced nurses feel more confident in titrating sedation to patient condition
(Walker & Gillen, 2006; Weir & O’Neill, 2008). However, research on workarounds, or
behaviors employed by nurses to bypass perceived obstructions in their workflow, has
shown that greater seniority and expertise in critical care may make nurses more likely to
5

deviate from standard protocols that they consider to be unimportant or not useful
(Debono et al., 2013). Observed differences in adherence to sedation management
protocols across clinician groups (Burns 2012; Ista, de Hoog, Tibboel & van Dijk, 2009;
Weir & O’Neill, 2008) suggest that nurses are susceptible to developing professionally
cultivated attitudes toward the care of children requiring sedation, which in turn impact
their management of patients.
Pediatric critical care nurses function within a team of providers. The teamwork
required by PICU care necessitates interaction among multiple providers who may bring
varying perspectives and levels of knowledge or skill to the management of pediatric
sedation (Schechter, Berde, & Yaster, 2003; E. J. Thomas, Sexton, & Helmreich, 2003).
The knowledge base surrounding sedation management is currently divided across
numerous fields (Schechter et al., 2003). Research has attempted to ensure consistent
communication across disciplines regarding sedation through the use of objective
measurement scales, such as the State Behavioral Scale (SBS) (Curley, Harris, Fraser,
Johnson, & Arnold, 2006) and the Withdrawal Assessment Tool-version 1 (WAT-1)
(Franck et al., 2008; Franck et al., 2012). But these assessment tools have not yet been
fully integrated in practice (Larson, Arnup, Clifford, & Evans, 2013) and are not
thoroughly embedded in clinical decision-making. This may be because nurses have
reported using both their clinical judgment and assessment tools together (Walker &
Gillen, 2006) or a result of inconsistent use of these tools among members of the clinical
team (Weir & O’Neill, 2008).
Lack of interprofessional collaboration and nurse autonomy (Olmstead, Scott, &
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Austin, 2010; Schechter et al., 2003; E. J. Thomas et al., 2003) may complicate the
process of providing sedation therapy in the PICU. One survey found that only 55% of
nurses felt that nurses and physicians communicated clearly regarding sedation goals
(Walker & Gillen, 2006). Nurses attempting to implement sedation protocols may be
frustrated by other providers’ lack of adherence (Weir & O’Neill, 2008), which may
serve to decrease their apparent or actual protocol compliance. For example, in a recent
study of nurses’ satisfaction with using the WAT-1 for patient assessment, 90% of nurses
reported that the WAT-1 was a helpful tool in their practice but they also cited a lack of
physician willingness to change the patient’s weaning plan on the basis of assessment
findings (Suddaby & Josephson, 2013). This reluctance persisted despite reported
improvements in communication about sedation and weaning with the implementation of
withdrawal assessments.
Nurses caring for children requiring sedation operate within high-volume units,
which may struggle with low nurse-to-patient ratios or insufficient staffing, both of which
have been shown to increase the risk of iatrogenic patient complications (Carayon &
Gürses, 2005; Tubbs-Cooley, Cimiotti, Silber, Sloane, & Aiken, 2013). Specifically with
regard to sedation and analgesia management, unit volume and staffing have been found
to have a complex relationship with protocol or guideline implementation and adherence:
standard protocols may be more likely to be used in larger units (i.e., ≥20 beds), (Tanios,
de Wit, Epstein, & Devlin, 2009; Gharavi et al., 2007), but the effect of written
guidelines on increasing attention to sedation and analgesia may only last until the point
at which high unit volumes and poor staffing serve to decrease compliance (Slomka et al.,

7

2000). In contrast, the literature on nursing workforce issues has highlighted Magnetdesignated hospitals as excellent work environments, with improved nurse and patient
outcomes (McHugh et al., 2013). The potential impact of nurse staffing, workloads, and
work environments, including the influence of working in a Magnet versus non-Magnet
institution on patient outcomes on sedation for mechanical ventilation, remains
unexplored.
Achieving an optimal level of sedation – that is, one that makes a child safe and
comfortable during the course of their mechanical ventilation using the lowest amount of
sedation possible – is a key objective of comfort management in the PICU (Johnson et
al., 2012; Playfor et al., 2006). However, adequately sedating critically ill children
remains an elusive goal in practice: a recent review of sedation assessments in PICUs
around the world found that up to 32% of patients are over-sedated and 11% are undersedated after pooling observations from a variety of different assessment methods (Vet et
al., 2013). Only 58% of children were adequately sedated over the course of the study
period. Over-sedation is particularly problematic, as it is associated with numerous
clinical problems, including longer duration of mechanical ventilation, extubation failure,
and greater cumulative drug exposure (Randolph et al., 2002), which contribute to
development of medication tolerance, physical dependence and subsequent iatrogenic
withdrawal syndrome (Fonsmark, Rasmussen, & Carl, 1999; Ista et al., 2008). Undersedation is equally detrimental, as the associated agitation and distress in a confused and
disoriented child can result in accidental displacement of intravenous lines or
endotracheal tubes (Sorce, 2005) and intolerance of mechanical ventilation (Cheifetz,
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2003). Resulting complications can include unplanned endotracheal intubation, airway
trauma, hemodynamic instability, and increased lengths of mechanical ventilation and
higher mortality (Cheifetz, 2003; Playfor et al., 2006; Vet et al., 2013), not to mention
distress for both patients and their parents (Playfor, Thomas, & Choonara, 2000).
Tolerance
Pharmacodynamic tolerance is a purely biochemical phenomenon, characterized
by decreased efficacy of a drug over repeat exposures due to cellular adaptation to ongoing receptor binding, such that an increased dose or concentration of a drug is required
to produce the same patient response (Barr et al., 2011; Jenkins, 2011). In animal and
human models, opioid tolerance is mediated by opioid and N-methyl-D-aspartate
(NMDA) receptors in the central nervous system. Normally, opioid-receptor binding
causes activation of inhibitory G-proteins and down-regulation of intracellular adenylyl
cyclase levels, which are responsible for the clinical effects of analgesia and sedation
(Jenkins, 2011; Smith, 2009; Suresh & Anand, 2001). However, following opioid
exposure, receptor desensitization leads to a paradoxical hyper-sensitization of this
signaling pathway, mediated by down-regulation or internalization of opioid receptors
and uncoupling of opioid receptors from inhibitory G-proteins (Suresh & Anand, 2001).
Excitatory NMDA receptor interactions contribute to the development of opioid tolerance
by increasing intracellular calcium and activating other neural depolarization pathways.
The end result of these cell-level changes is hyperalgesia, or increased perception of pain
and agitation, rather than the expected opioid-induced analgesia and sedation (Anand et
al., 2010; Jenkins, 2011; Suresh & Anand, 2001).
9

Benzodiazepine tolerance is hypothesized to develop in a similar manner: drug
binding to neuronal γ-aminobutyric acid (GABA) receptors leads to inhibitory effects on
neurotransmission, but chronic exposure may cause receptor modifications and
uncoupling, excitatory glutaminergic neurotransmission, and an increase in NMDA
receptors (Allison & Pratt, 2003; Vinkers & Olivier, 2012). The current model suggests
that a synergistic combination of most or all of these cellular changes causes
benzodiazepine tolerance.
Although the biochemical mechanisms underlying the development of tolerance
are common across individuals, there is also variability in the degree of tolerance that
patients develop, which may be impacted by factors unique to the individual. For
example, in children in particular, age and developmental stage influence the
pharmacodynamics of sedation therapy. The CYP2D6 and CYP34A enzymes involved in
metabolism of opioids and benzodiazepines may not fully mature until 6 months of age,
placing younger children at increased risk for altered responses to these medications
(Johnson, Miller, & Hagemann, 2012; Mulla, 2010). Pharmacodynamic idiosyncrasies in
the developmentally diverse PICU population present problems for clinicians to use these
sedatives effectively and safely.
Other studies have demonstrated racial and ethnic differences in drug metabolism
as a consequence of pharmacogenetic variations within populations. Approximately 7%
of the white population and up to 30% of the African American population possess
alterations in the CYP2D6 enzyme associated with rapid metabolism, placing African
Americans at greater risk of experiencing increased drug effects with typical doses

10

(Smith, 2009). Similarly, up to 34% of African American patients are affected by
deficient CYP2D6 enzymes, increasing their risk for adverse drug reactions (Brennan,
2012). Since tests of enzyme functionality are not routinely performed in the clinical
setting, age, race and ethnicity may be the only surrogate variables available for
understanding their potential mediating or moderating effects on the development of
tolerance and physical dependence.
Severity of illness and clinical status are complex variables impacting the
metabolism of sedative drugs (Carcillo et al., 2003; Ince et al., 2012), and therefore the
quality of sedation management and the duration of exposure to sedatives. Specifically,
hepatic and/or renal impairment associated with critical illness may significantly increase
the bioavailability of certain drugs, such as morphine (Brennan, 2012; Smith, 2009).
Children in the PICU also may experience frequent and rapid changes in clinical status,
and the extent to which multiple organ failure or other severe illness states influence
sedation therapy and drug tolerance remains to be evaluated thoroughly, though limited
research exists (Bergman, Steeves, Burckart, & Thompson, 1991; Dagan, Klein, Bohn, &
Koren, 1994; Fonsmark et al., 1999; Hughes et al., 1994; Ince et al., 2012). Similarly,
neurologic impairments and/or developmental delays may influence the way in which
critically ill children respond to sedative agents, or exhibit behaviors typically managed
with sedating medications. Similar to the unique nuances that the organizational context
brings to bear on sedation management in the PICU, variability in patient response to
analgesic and sedative medications presents a unique challenge in the study of drug
tolerance, physical dependence and subsequent iatrogenic withdrawal syndrome.

11

Weaning and Iatrogenic Withdrawal Syndrome
After recovery from their primary illnesses, children are able to resume
responsibility for ventilation and oxygenation, which begins the process of gradual
weaning of mechanical ventilation and associated sedation. Discontinuation of
mechanical ventilation without adequate sedation weaning can lead to respiratory
depression necessitating endotracheal reintubation, which is associated with worse patient
outcomes (Cheifetz, 2003). Failure to wean sedative therapy is also problematic, as it is
directly related to IWS in physically dependent patients (Cho, O’Connell, Cooney, &
Inchiosa, 2007; Darnell, Steiner, Szmuk, & Sheeran, 2010; Ducharme, Carnevale,
Clermont, & Shea, 2005; Ista, van Dijk, Gamel, Tibboel, & de Hoog, 2007; Jacobs,
Salman, Cotton, Lyons, & Brilli, 2001). IWS is a cluster of physiologic signs and
symptoms reflecting autonomic nervous, gastrointestinal and cardiovascular disruptions
(e.g., elevated temperature, vomiting, tachycardia). Not only does IWS add to patient
discomfort, but also it extends intensive care and hospital lengths-of-stay (Franck,
Vilardi, Durand, & Powers, 1998), and creates stress for parents and caregivers (Johnson
et al., 2012). The added costs can be considerable.
Assessment and Management of IWS
As pediatric critical care clinicians have come to acknowledge IWS as a
complication of PICU care, a large volume of research has been directed towards
identifying and assessing its severity. Two instruments were developed concurrently in
the United States and the Netherlands, respectively, and tested for use in the PICU: the
Withdrawal Assessment Tool-Version 1 (WAT-1) (Franck et al., 2008; Franck et al.,
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2012) and the Sophia Observation withdrawal Symptoms-scale (SOS) (Ista et al., 2008;
Ista, de Hoog, Tibboel, Duivenvoorden, & van Dijk, 2013). The WAT-1 is an 11-item
instrument that consists of four separate assessments performed by the bedside nurse:
review of the patient’s medical record for the past 12 hours, direct observation of the
patient at rest for 2 minutes, application of progressive stimulus with simultaneous
patient assessment, and assessment of post-stimulus recovery time (Appendix 1). The
instrument was developed and validated for use in a sample of 83 pediatric patients
between 2 weeks to 18 years of age who were recovering from acute respiratory failure
and had received greater than 5 days of continuous or around the clock opioid
medications (Franck et al., 2008). The WAT-1 screens for symptoms of IWS attributable
to either opioid- or benzodiazepine-associated withdrawal, with scores ranging from 0 to
12 points. A cutoff score of ≥ 3 is considered to be indicative of IWS and has high
sensitivity and specificity (87% and 88%, respectively; area under the curve 0.94 ± 0.01
[95% confidence interval (CI) 0.93-0.96]) (Franck et al., 2008). In addition to being used
as a screening tool for the presence of IWS, peak WAT-1 scores have demonstrated high
convergent validity with nurse ratings of withdrawal intensity (rs = 0.80), and were
moderately correlated with lengths of opioid and benzodiazepine therapy in the preweaning period and length of opioid weaning (Franck et al., 2008), providing further
evidence for the instrument’s construct validity. Therefore, peak WAT-1 scores might
also be used as an indicator of the severity of IWS symptoms.
The Sophia Observation withdrawal Symptoms-scale (SOS) is another tool
developed by pediatric experts for evaluating symptoms of IWS in critically ill children.
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The SOS demonstrated very good reliability and validity in psychometric testing (83%
and 93%, respectively), and a cutoff score of ≥ 4 yielded good sensitivity and specificity
for identifying IWS (Ista et al., 2013; Ista, van Dijk, de Hoog, Tibboel, &
Duivenvoorden, 2009). The authors suggest that the tool improves upon the WAT-1 by
including more signs and symptoms of IWS, such as anxiety, grimacing, and tachycardia
(Ista et al., 2008; Ista et al., 2009). However, a direct comparison of the two instruments
has never been performed. Neither the WAT-1 nor the SOS is able to distinguish between
opioid-related versus benzodiazepine-related IWS, since most pediatric patients receive
both for sedation and are typically weaned from both concurrently (Ista et al., 2007). It is
important to note that monitoring for IWS is not a standard practice in all institutions.
The treatment of IWS is also an area of significant research interest. Currently,
there are no evidence-based guidelines for the treatment of IWS in children; clinicians
instead must rely upon their clinical judgment and guidelines for the management of
neonatal abstinence syndrome in infants born to substance dependent mothers (American
Academy of Pediatrics, 1998; Hudak, Tan, The Committee on Drugs, & The Committee
on Fetus and Newborn, 2012). The American Academy of Pediatrics recently released a
clinical report recommending that patients be transitioned to longer-acting opioid
formulations, followed by 10-20% dose reductions of short-acting opioids every 24 to 48
hours as tolerated until all opioids are discontinued in order to prevent IWS (Galinkin,
Koh, The Committee on Drugs, & Section on Anesthesiology and Pain Medicine 2014).
Benzodiazepine-related IWS has been treated with long-acting benzodiazepine
supplementation, as well as substitution of phenobarbital (J. D. Tobias, 2000). Numerous
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studies have evaluated the potential for other sedative medications to prevent (i.e.,
methadone) or manage the symptoms of IWS: clonidine, dexmedetomidine, and ketamine
have all been found to effectively facilitate weaning from opioids and benzodiazepines
(Anand et al., 2010; Aydogan et al., 2013; Hünseler et al., 2014; Lugo, MacLaren, Cash,
Pribble, & Vernon, 2001; Meyer & Berens, 2001; Tobias, 2006; White & Karsli, 2007).
It is important to note that IWS continues to develop in PICU patients despite the
implementation of protocols intended to prevent it (Bowens et al., 2011; Ducharme,
Carnevale, Clermont, & Shea, 2005; Johnson, Harrison, & Allen, 2010; Meyer & Berens,
2001; Siddappa et al., 2003; Tobias, 2006). For example, few PICUs have integrated
weaning protocols into their standards of care (Alexander, Carnevale, & Razack, 2002;
Deeter et al., 2011; Ista, de Hoog, Tibboel, & van Dijk, 2009; Jin et al., 2007), and among
those that have, protocol compliance remains a challenge (Burns, 2012; Guttormson et
al., 2010). Although in a survey of US PICUs, 100% of physicians reported gradually
weaning patients from sedative and analgesic drugs, 94% also reported that children
experienced IWS symptoms on their units (Twite et al., 2004). This continued incidence
of IWS is presumably related to the wide variation in both sedation and weaning
protocols, and practice.
Two decades of research has aimed to better characterize IWS and to define its
precipitating factors. The two classically identified clinical factors impacting IWS are
cumulative dose and duration of sedation. After Finnegan et al. (1975) first identified the
phenomenon of withdrawal in neonates born to substance dependent mothers, Arnold et
al. (1990) extended the concepts of tolerance and physiologic dependence to a
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retrospective study of neonates sedated for extracorporeal membrane oxygenation
(ECMO). They found that cumulative doses of fentanyl exceeding 1.5mg/kg and duration
of ECMO (and therefore sedation) >5 days were significantly associated with higher odds
of IWS (OR = 7.0 and 13.9, respectively). Katz, Kelly and Hsi (1994) subsequently
conducted a prospective study of the occurrence of IWS in slightly older critically ill
children (aged 1 week to 22 months) receiving mechanical ventilation and continuous
infusions of fentanyl. They identified that a threshold cumulative fentanyl dose of
1.6mg/kg and an infusion duration exceeding 9 days were 100% predictive of IWS.
Meanwhile, Fonsmark, Rasmussen and Carl (1999) found no associations between IWS
and cumulative morphine dose, but total doses of midazolam >60 mg/kg were associated
with the incidence of IWS. Until recently, no threshold duration of therapy for
benzodiazepines was associated with IWS; however, a retrospective study found that a
duration of benzodiazepine therapy exceeding 5 days was predictive (Fernández-Carrión
et al., 2013).
Several cutoff doses and durations of therapy have been proposed (Amigoni et al.,
2014; Arnold et al., 1990; Dominguez, Lomako, Katz, & Kelly, 2003; Fonsmark et al.,
1999; Franck et al., 1998; Katz et al., 1994), but the diversity of patient populations in the
PICU and variance in sedation, weaning, and assessment for IWS has resulted in a lack of
consensus regarding contributors to IWS. These results strongly suggest that other
contextual variables influence a child’s risk for developing IWS. The current biomedical
model fails to adequately explain the ongoing incidence of IWS in critically ill children
and differential susceptibility between patients. Therefore, the purpose of this dissertation
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study was to investigate the development of IWS in critically ill children requiring
sedation therapy by exploring variables at the levels of the individual patient, the process
and the health care system.
Operational Definitions
Conceptual definitions of tolerance and IWS have been presented in the previous
sections. However, for the purposes of the proposed study, a set of operational definitions
is needed for key variables of interest that will be referenced throughout the three studies.
In particular, standardized instruments were used to assess variables, beginning with the
primary outcome of IWS.
As discussed, the WAT-1 (Appendix 1) is an 11-item instrument developed for
the purpose of detecting signs and symptoms of clinically significant IWS in children
(Franck et al., 2008; Franck et al., 2012). Prior to the start of the RESTORE trial, all
clinicians across the 31 participating institutions were trained in the use of WAT-1
scoring and completed a post-test to ensure their comprehension of the material (Curley
et al., 2015). After baseline training, each RESTORE nurse co-investigator provided five
sets of paired WAT-1 ratings. Scores were evaluated for inter-rater reliability and
maintained at greater than 90% throughout the study. Therefore, for the purposes of this
dissertation work, WAT-1 scores were used as a valid and reliable indicator of the
presence and severity of IWS in study subjects, with the outcome of clinically significant
IWS being operationally defined as two or more non-consecutive WAT-1 scores ≥3. In
the RESTORE trial, clinically significant withdrawal was defined as the need for rescue
therapy (i.e., an opioid or benzodiazepine bolus or increase in opioid or benzodiazepine
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infusion) after the start of weaning in order to manage worsening symptoms, which were
identified using the WAT-1 (Grant, Scoppettuolo, Wypij, & Curley, 2012). However, due
to variations in clinical practice across institutions, not all patients in the RESTORE trial
exhibiting signs and symptoms may have received rescue therapy, particularly among
control PICUs. In contrast, all sites were required to assess patients using the WAT-1 for
symptoms of IWS during sedation weaning, and the threshold score of ≥ 3 has been
psychometrically tested (Franck et al., 2008; Franck et al., 2012). Out of concern for
potential false positives, the more conservative criterion of two WAT-1 scores ≥3 was
used, which has not been previously tested for validity and reliability.
A variety of analgesic and sedative medications are available for use in the PICU
(Vet et al., 2013; Zuppa et al., 2005), but this study will focus on the specific
contributions of opioids and benzodiazepines to the outcome of IWS. Total sedative
exposure was measured by aggregating daily dosing of sedative medications in the
RESTORE trial. All opiates were converted to morphine sulfate equivalents, and all
benzodiazepines were converted to midazolam equivalents, according to standard
conversions: morphine equivalent conversion factors to equal 1mg morphine sulfate were
15µg remifentanil; 15µg fentanyl; 0.15mg hydromorphone; and 0.3mg methadone, and
midazolam equivalent conversion factors to equal 1mg midazolam were 0.2mg
clonazepam; 0.3mg lorazepam; and 2mg diazepam (Curley et al., 2015).
A limitation of previous investigations is that they did not adequately differentiate
between pre- and post-start of weaning medication doses, making previously proposed
dose and duration thresholds unusable for prognostic purposes. Therefore, all medication-
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related variables in this dissertation study were limited to the preweaning period:
Cumulative doses (in milligrams per kilogram [mg/kg]) were calculated by summing
continuous, scheduled and intermittent doses of each agent during the pre-opioid weaning
period and dividing by the dosing weight. The mean daily dose was calculated by
dividing the cumulative dose by the number of days the specific drug was administered.
The peak daily dose was equal to the highest daily dose of each drug administered.
Duration of opioid and/or benzodiazepine therapy was recorded based on the total
number of days the patient received each agent.
Although it is commonly supposed that children with previous sedative exposures
have greater medication needs and thus are more likely to demonstrate tolerance with
subsequent exposures, studies have failed to support such an association. Children with a
history of opioid exposure do not have higher opioid requirements during or following
surgery (Fanning, Stucke, Christensen, Cassidy, & Berens, 2012), and in fact tolerance
appeared to occur less frequently among subjects with previous PICU admissions in one
study (Anand et al., 2013). Therefore, a history of exposure to opioids and/or
benzodiazepines was not examined in either the RESTORE trial or this secondary
analysis, and was not expected to significantly impact the results.
Tolerance was recently investigated in a multicenter observational study, in which
it was defined as a doubling of the initial (i.e. first 24 hours’) opioid dose over the course
of a patient’s hospitalization (Anand et al., 2013). In the absence of clear biomarkers for
the development of tolerance, a clinically based definition is the closest available
surrogate. For the purposes of this study, the current operational definition of tolerance
was adapted to define tolerance as a doubling of the Day 2 opioid dose, with the caveat
19

that tolerance had to occur before the onset of opioid weaning. This modification was
needed to adjust for potential sub-optimal dosing of the initial sedative regimen.
Chapter Aims and Rationales
Chapter 2: Specific Aims.
The purpose of this systematic review of available literature was to identify
known or potential risk factors contributing to the prevalence of iatrogenic withdrawal
syndrome (IWS) in critically ill children. This paper presents a conceptual model of risk
for IWS, which demonstrates the relationships among tolerance, the identified risk
factors, and the outcome of clinically significant IWS. Furthermore, the results of this
review provide the foundation for the data-based papers to follow. The manuscript was
published in the January 2015 issue of Pediatric Critical Care Medicine.†
Rationale.
The conceptual model in this paper was developed through an inductive process
of examining the literature and collapsing related risk factors into categories, without any
basis in previous theories. However, the classic structure-process-outcome model
implemented in healthcare research (Donabedian, 1966) provides a useful framework for
understanding the conceptual distinctions made between variables at the process and
system levels in this model of IWS risk. To summarize, the structure of a healthcare
organization consists of characteristics that indirectly influence patient outcomes by
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shaping the environment of care delivery. Typically these features remain stable over
time, and include factors such as hospital size and staff professionalization (Hearld,
Alexander, Fraser, & Jiang, 2008). In contrast, processes are care activities performed by
individuals within the organization, which are by their nature dynamic and changing over
time. The benefit of simultaneously considering patient-, process- and system-level
factors together is the ability to identify potential interactions between process and
systems variables that contribute to patient outcomes (Hearld et al., 2008), while
adjusting for differences in patient populations across healthcare institutions.
Chapter 3: Specific Aims.
The purpose of this paper was to use data from baseline pre-randomization
subjects in the RESTORE trial to further evaluate the relationships among tolerance,
weaning, and IWS. Specifically, patterns of opioid and benzodiazepine weaning as they
occurred in PICUs across the United States in typical practice settings was assessed and
characterized. The information obtained about the effects of sedative dose, duration, and
other clinical factors on tolerance and subsequent patterns of weaning provide key
information for the construction of a predictive model in the final paper. This manuscript
has been submitted for review for publication.
Rationale.
The pre-randomization RESTORE subjects provided a unique cohort for exploring
the relationships of interest in this study, since similar data were collected as in the larger
trial and subjects were assessed for pain, agitation, sedation and IWS using validated
assessment instruments. Therefore, unlike other observational studies that may rely on
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clinicians’ subjective assessments of these patient states or retrospective chart reviews,
this dataset contained rigorously measured data points that reflected usual practice at each
institution. Some of the participating PICUs had standardized sedation assessment
processes already in place, but they were not necessarily being used to titrate or wean
sedative therapy. These circumstances offered a view of usual practice prior to
implementation of a standardized, goal-directed protocol. This dataset also provided a
test group for developing a standard approach to defining start of opioid weaning,
tolerance, and weaning patterns in a smaller, more manageable patient cohort.
Chapter 4: Specific Aims.
The purpose of this paper was to build upon the findings of the previous two
investigations, in order to construct a predictive model of IWS risk using data from
subjects in the RESTORE trial. The resulting model could be used as the foundation for a
risk assessment tool that would help guide weaning and other preventive strategies in the
clinical setting. This manuscript has been submitted for review for publication.
Rationale.
Up to this point, there have been a few attempts to identify risk factors for IWS
(Amigoni et al., 2014; Dominguez et al., 2006; Dominguez et al., 2003; FernándezCarrión et al., 2013; Ista et al., 2013), which have met with varying degrees of success.
Key limitations of these previous approaches have been: sampling from a single center,
use of small study samples, and failure to distinguish between preweaning medication
doses. Results of these analyses have been inconsistent, even with respect to the most
widely reported risk factors of sedative dose and duration (Amigoni et al., 2014;
22

Dominguez et al., 2003; Fernández-Carrión et al., 2013). In addition, older studies have
been hampered by a lack of standardized assessment instruments for IWS ((Birchley,
2009).
The convergence of a number of factors therefore supports the development of a
new predictive model of IWS in this study. First, the recently completed RESTORE trial
was the largest study of sedation management ever conducted in pediatric critical care,
and the dataset was designed with the objective of evaluating IWS as a secondary
outcome. Routine screening for IWS was performed using the WAT-1, a well-validated
instrument that is being used in an increasing number of studies of IWS (Amigoni et al.,
2014; Fisher, Grap, Younger, Ameringer, & Elswick, 2013; Jeffries, McGloin, Pitfield, &
Carr, 2012). Finally, the trial was multi-center, which provided the opportunity to
examine the influence of a diverse group of providers and health systems on the outcome
of interest, an area that has previously been underexplored in the literature.
Strengths and Limitations
This dissertation had the benefit of using data from the largest clinical trial of
sedation management ever conducted in pediatric critical care for secondary analysis. The
research question of the RESTORE trial – whether pediatric patients with acute
respiratory failure managed per a nurse-led, goal-directed sedation management protocol
experienced fewer days of mechanical ventilation – was directly related to the outcomes
of interest in the analyses to follow. Not only were relevant data points collected using
the stringent site auditing, data monitoring and quality control processes of a large
clinical trial, but the incidence of IWS was also a secondary outcome measure of the
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RESTORE trial. Thus, it was both feasible and justifiable to conduct a secondary analysis
of this existing data set to address the specific aims of this dissertation.
However, because two of the three studies were secondary analyses, the findings
are limited by any weaknesses of the parent study. Although highly unlikely, site
randomization of the RESTORE trial may have failed to yield a representative sample of
critically ill children in the PICU, impacting generalizability of the results. Undetectable
differences between the control and intervention sites may have occurred, potentially
confounding the effect of the nurse-led, goal-directed intervention. Finally, this
dissertation included process- and system-level variables in its analyses, based on an
untested conceptual framework. Since clinical sites reported their data in aggregate, the
influence of systems factors could not be linked to individual patients. Therefore, any
conclusions drawn by this study regarding the contributions of system-level variables to
the development of IWS will require prospective validation in future studies. Since
prospective data collection did not take place for these dissertation analyses, both the
approach and findings are limited to the data collected during the course of the RESTORE
trial.
Significance
The variables driving the development of IWS, beyond the biologic and
pharmacologic level, are presently uncharacterized and pose a critical barrier to progress
in IWS science. This study provides valuable evidence and context for understanding the
phenomenon of IWS within the unique clinical circumstances in which it occurs. The
results of these three studies will advance our current approach to management of
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symptoms of IWS in the PICU. In particular, prospective validation of the predictive
model of IWS risk contributed by this study is a logical next step towards a robust
program of research, and further studies would harness these empirically demonstrated
risk factors to support future projects, for example identifying biomarker changes
associated with IWS in critically ill children.
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Abstract
Objective: Analgesia and sedation are common therapies in pediatric critical care, and
rapid titration of these medications is associated with iatrogenic withdrawal syndrome
(IWS). We performed a systematic review of the literature to identify all common and
salient risk factors associated with IWS and build a conceptual model of IWS risk in
critically ill pediatric patients.
Data sources: Multiple databases, including PubMed/Medline, EMBASE, CINAHL, and
the Cochrane Central Registry of Clinical Trials were searched using relevant terms from
January 1, 1980 to August 1, 2014.
Study selection: Articles were included if they were published in English and discussed
IWS following either opioid or benzodiazepine therapy in children in acute or intensive
care settings. Articles were excluded if subjects were neonates born to opioid- or
benzodiazepine-dependent mothers, children diagnosed as substance abusers, or subjects
with cancer-related pain; if data about opioid or benzodiazepine treatment were not
specified; or if primary data were not reported.
Data extraction and synthesis: In total 1395 papers were evaluated, 34 of which met the
inclusion criteria. Most papers were prospective observational or interventional studies.
To facilitate analysis, all opioid and/or benzodiazepine doses were converted to morphine
or midazolam equivalents, respectively. A table of evidence was developed for
qualitative analysis of common themes, providing a framework for the construction of a
conceptual model.
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Findings: The strongest risk factors associated with IWS include duration of therapy and
cumulative dose. Additionally, evidence exists linking patient, process and system factors
in the development of IWS.
Conclusions: Given the state of existing evidence, well-designed prospective studies are
required to better characterize IWS in critically ill pediatric patients. This review
provides data to support the construction of a conceptual model of IWS risk that, if
supported, could be useful in guiding future research.
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Introduction
Sedation is commonly used in pediatric intensive care to reduce the physiologic
and psychological stress associated with critical illness. However, it is known that rapid
weaning or abrupt cessation of sedation therapy in drug tolerant children precipitates
iatrogenic withdrawal syndrome (IWS)1 – a cluster of symptoms that can have deleterious
effects on patient recovery and hospitalization.2–4
The prevailing mechanistic theory of drug tolerance involves receptor
desensitization and up-regulation of excitatory intracellular pathways.5–7 Anand et al.
provide a comprehensive review of physiologic mechanisms in pharmacodynamic
tolerance.2 Clinically, tolerance manifests as a need for increased medication to achieve
consistent therapeutic effects. Tolerance, escalating doses, and prolonged treatment are
coupled with the development of physiologic dependence. Once patients manifest
tolerance and dependence, termination of therapy without measured weaning precipitates
IWS.3
Most studies on opioid and benzodiazepine IWS have focused on characterizing
symptoms in the pediatric population, developing screening and assessment tools, or
testing treatment regimens. A fundamental question in understanding IWS has been
overlooked: what specific factors predispose pediatric intensive care unit (PICU) patients
to developing IWS? Knowledge of IWS risk factors and their inter-relationships may help
clinicians prevent IWS. We performed a systematic review of the literature to identify all
common and salient risk factors associated with IWS, with the intention of building a
conceptual model of IWS that will guide future research.
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Methods
PubMed/Medline, EMBASE, CINAHL, and the Cochrane Central Registry of
Clinical Trials were searched for original research on opioid- and/or benzodiazepinerelated IWS in critically ill children. Given the limited number of studies in this area,
time limits were set between January 1, 1980 and August 1, 2014. Corresponding
exploded MeSH or EMTREE terms were used when possible (Table 2-1).
Articles published in English and discussing IWS following either opioid or
benzodiazepine therapy in children in intensive care settings were included. Age limits
were set from 2 weeks post-gestation to 18 years. Articles were excluded if data about
opioid or benzodiazepine treatment were not specified; if primary data were not reported;
or if subjects were neonates born to opioid- or benzodiazepine-dependent mothers,
children diagnosed as substance abusers, or subjects with cancer-related pain. Relevant
reviews were referenced to capture key studies missed by the search criteria, using
ancestry searching.
Study data were extracted into tables of evidence and qualitatively synthesized.
Examined data points included study population, location, sample size, sedative
medications and mode of administration, IWS assessment method, weaning method, and
number and percentage of IWS subjects. For cross-study comparisons, opioid and
benzodiazepine doses were converted to morphine and midazolam equivalents.
Specifically, morphine equivalent conversion factors to equal 1mg morphine sulfate were
as follows: 15µg remifentanil; 15µg fentanyl; 0.15mg hydromorphone; and 0.3mg
methadone.8 Midazolam equivalent conversion factors to equal 1mg midazolam were:
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0.2mg clonazepam; 0.3mg lorazepam; and 2mg diazepam. Qualitative analysis of the
retrieved articles’ results was used to identify both common and novel factors and
construct categories of risk. The authors then used an iterative consensus process to
develop a conceptual model describing IWS risk that was organized to include patient,
process, or system factors contributing to IWS in pediatric patients.
PRISMA guidelines were followed in the conduct and reporting of this study,
including consultation with a research librarian in designing the search strategy.9 Selected
studies were evaluated for quality using a criteria-based assessment method for
randomized controlled trials (adequacy of randomization and blinding, presence of
allocation concealment, and intention-to-treat analysis)10 and the Newcastle-Ottawa
Quality Assessment Scale for observational studies.11 Randomized controlled trials were
rated high, medium and low quality, with a single category deduction for each missing
criterion. The Newcastle-Ottawa Quality Assessment Scale assigns star ratings for
important elements of observational study design, with a maximum possible score of nine
stars. Studies were rated high (7-9 stars), medium (4-6 stars) or low quality (1-3 stars)
based on the total number of stars received.
Results
As outlined in Figure 2-1, 34 data-based articles met inclusion criteria for this
review. Twenty-three studies reported combination opioid and benzodiazepine therapy
(Table 2-2), while 9 reported opioid-only therapy (Table 2-3), and two reported
benzodiazepine-only therapy (Table 2-4) (Supplemental Digital Content).
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The majority of articles (74%) included <50 subjects. The incidence of either opioid- or
benzodiazepine-related IWS (Figure 2-2) was widely variable; for example, frequency of
IWS symptoms attributable to cessation of either opioids or benzodiazepines in studies of
concurrent therapy ranged from 5%12 to 87%.13
Common themes suggested three categories of risk factors associated with IWS:
patient-, process-, and system-level factors, which were synthesized into a conceptual
model (Figure 2-3) that organizes the presentation of evidence in this review. The
majority of studies investigated patient-level variables, including age, criticality, duration
of therapy and cumulative dose. Process-level factors were directly related to the
approach of providing sedation, and included the use of sedation and/or IWS assessment
tools and protocols. System-level factors were infrequently cited, but reflected structural
variables that influence clinician practice within the healthcare system, such as
interprofessional collaboration and protocol compliance. Each will be presented in the
following sections.
Patient-Level Factors
Age. Moderate quality evidence supports a relationship between age and IWS.14–
20

Prospective studies have shown that cumulative opioid dose is related to age,16 and that

younger patients experience higher incidences of IWS.18 Similarly, among retrospective
studies assessing the abrupt cessation of continuous fentanyl15 or midazolam infusions,19
younger age was associated with neurologic symptoms of IWS, such as
irritability/agitation and seizures.
Older age was also associated with IWS in children.17 For example, subjects with
the highest daily doses (morphine >60 µg/kg/hr or midazolam >250 µg/kg/hr) tended to
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be older (median 6 years vs. 1.4; p=0.0017) even when doses were adjusted for weight.20
These subjects also had a greater incidence of IWS: 40% of older subjects versus 12% of
other subjects (p≤0.001).
Criticality. Limited data from moderate quality studies suggests that severity of
illness, particularly involving brain injury or ischemia, contributes to a higher incidence
of IWS.19–24 Low serum albumin concentration in infants receiving midazolam in one
retrospective study was associated with IWS-related neurologic disturbances.19 Several
studies noted that children with pre-existing seizure disorders or hypoxemic brain injuries
are more likely to experience IWS.20–23
Duration of therapy. Many studies of varying quality related duration of opioid
and/or benzodiazepine therapy to the incidence of IWS.1,4,8,16,17,25–35 Subjects with longer
PICU or hospital lengths of stay,8,29 more ventilator days,8,29 and longer ECMO
therapy4,28 were more likely to experience IWS. In one paper, subjects in a randomized
trial of methadone-facilitated weaning were more likely to experience treatment failure
with longer PICU lengths of stay, particularly after receiving fentanyl for ≥9 days.29 In
two small studies, subjects experiencing IWS received at least 10 days of opioid or
benzodiazepine therapy.34,35
The majority of studies in this category directly evaluated relationships between
length of opioid and/or benzodiazepine therapy and IWS.1,8,16,17,25–27,30–33,36 Some used
statistical methods to establish predictive opioid thresholds, with cut-off lengths of
therapy ranging from ≥527 to 8 days (OR=18, p= 0.02).25 Exposures longer than 9 days
were 100% predictive of IWS.27 The remaining studies evaluated correlations between
length of opioid infusion and IWS outcome or score,1,16,26,32 which ranged from
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moderately (r=0.20, p=0.02)1 to strongly positive (r=0.70, p<0.05).26 Among prospective
studies investigating the duration of opioid therapy and IWS, all exceeded the 5-day
threshold proposed in previous research (Figure 2-4).1,8,12,16,17,25–27,30
No widely accepted threshold duration of therapy for benzodiazepines currently
exists, although a recent retrospective study found that a duration of benzodiazepine
therapy exceeding 5 days had 83% sensitivity and 92% specificity for predicting IWS.36
Positive correlations between duration of benzodiazepine therapy and IWS have been
identified in other studies of concurrent opioid and benzodiazepine
administration.1,8,17,30,31 Similar to opioid duration, these correlations are moderate,
ranging from r=0.23 (p<0.01)8 to r=0.52 (p<0.001).30 In several prospective studies,
subjects with IWS received benzodiazepine therapy in excess of 10 days (Figure
2-5).12,21,30,37
Dose. Strong reproducible evidence exists for a relationship between opioid
and/or benzodiazepine dose and IWS.1,4,8,12–14,16,17,20,21,23–30,32,35,36,38–40 Description of
dosing varied, with the most common measure being cumulative dose (total amount of
drug administered during treatment).
Several studies focused on the association between prescribed opioid dose and
IWS risk4,16,24–28,36,38 Whereas one study found that a cumulative morphine equivalent
dose of >106.7mg/kg was associated with 7-fold higher odds of IWS,28 another identified
that a threshold cumulative dose of ≥166.7mg/kg (morphine equivalents) was 100%
predictive of IWS.27 Lower thresholds have also been proposed in unique patient
populations, for example, >80mg/kg doses after ECMO support (OR=13.0, p=0.003).4
This threshold had 85% sensitivity and 70% specificity for predicting IWS. A more
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recent retrospective study found that 32 mg/kg morphine equivalent doses had 83%
sensitivity and 85% specificity for predicting IWS in children who received mean
cumulative doses of midazolam above published averages.36
Only one study of benzodiazepine-associated IWS compared cumulative dose
with the incidence of withdrawal,14 finding that an infusion rate greater than 0.3mg/kg/h
(midazolam equivalents) resulted in symptoms consistent with IWS. Cumulative dosages
in midazolam equivalents ranged from 0.9mg/kg to 25.3mg/kg,14 but statistical analyses
were not performed. However, in a study of mixed opioid and benzodiazepine
administration, a cumulative benzodiazepine dose threshold of >60mg/kg (midazolam
equivalents) was significant (p<0.05).23
Many studies evaluating IWS symptoms attributable to either opioids or
benzodiazepines reported dosage associations:1,8,12,13,17,20,21,23,29–31,34,35,39 one found
moderate correlations with opioid dose alone,31 and four with both opioid and
benzodiazepine dose.1,13,30,36 The remaining studies reported differences between groups
with and without IWS in cumulative opioid and/or benzodiazepine doses,8,12,17,23,29,39 or
had too few subjects for statistical analysis.21,34,35 The prospective studies were
graphically compared with the dose thresholds proposed for opioids (Figure 2-6) and
benzodiazepines (Figure 2-7), respectively. This analysis showed that many studies
reported mean or median doses well below the proposed thresholds among subjects with
IWS.1,12–14,17,21,30
Process-Level Factors
Sedation protocol. Although several authors have noted the importance of
standardized sedation protocols in reducing the incidence of IWS,12,40 little high-quality
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evidence exists to directly illustrate the proposed relationship. Three studies cited the lack
of a sedation management protocol as a risk factor for the development of IWS,12,31,40 and
two moderate-quality studies showed reductions in IWS rates in the intervention groups
when sedation protocols were implemented.12
Drug choice. Some evidence supports an association between drug choice and
IWS.4,13,15,17,20,33,34 Specifically, four studies observed an association between fentanyl
and IWS symptoms in children.4,13,15,41 Rates of IWS are lower in subjects receiving
morphine rather than fentanyl infusions (9% v. 57%; p=0.01).4,13 In a retrospective chart
review of subjects who developed a “movement disorder” following discontinuation of
infusions, fentanyl was the only medication common to all subjects (p<0.001).15
Methadone has been evaluated in several studies as a potential weaning agent to
prevent IWS symptoms in drug-tolerant pediatric patients.21,22,26,29,33,34,38,41 However, one
study33 determined that the greatest risk factor for IWS among subjects receiving
prophylactic methadone was inadequate methadone dosing. Multi-drug sedation therapy
has also been proposed as an additional risk factor for IWS.17,41
Mode of administration. Low to moderate quality articles reported more frequent
IWS among subjects receiving continuous infusions of opioids and/or
benzodiazepines.4,15,19,34,35,39,41 Although authors noted that continuous infusions could
theoretically contribute to faster development of drug tolerance,4,19,22 none of the studies
in this review specifically compared the effects of intermittent versus continuous
administration on the incidence of IWS.
Weaning. Fewer than half of the cited studies (43%) utilized a standardized
weaning protocol,4,12,13,22,25,27,29,30,32–34,37 and even with a standard protocol, withdrawal
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rates ranged from 5%12,34 to 87%.13 In the remaining studies, opioids, benzodiazepines, or
both were either abruptly discontinued19,23,24,35 or weaned on a variable basis.1,8,14–
17,20,26,28,31,39–41

Weaning patterns differed substantially: in one prospective study, opioid

dose changes in the first 24 hours of weaning ranged from −24mg/kg to +14mg/kg
(morphine equivalents).16 Two studies reported that use of a weaning protocol could
reduce the incidence of IWS.16,38 Some studies abruptly discontinued sedative therapy
due to the substitution of other agents, such as clonidine,16,20,41 dexmedetomidine,16,39
methadone,17,21,29,33,34,38,41 or ketamine.41 Despite prophylactic therapy, IWS still occurred
in 5%34 to 33%33 of subjects.
Sedation/withdrawal assessment. Although many studies of IWS have focused on
instrument development,1,8,13,17,30 few studies have evaluated the influence of routine
sedation assessment on the incidence of IWS. Some authors have commented on the
issues of over-sedation and development of tolerance,16,38,40,42 but no studies have
specifically evaluated relationships among adequate sedation, standardized assessment,
and IWS.
System-Level Factors
Weaning sedation requires a time-sensitive titration plan that may not be able to
be accomplished in the PICU when intensive care beds are limited. In addition, local
hospital-based policies may not allow for the use of some sedatives agents outside the
PICU. No paper cited in this review evaluated the impact of PICU census, bed
availability, or local policies regarding the use of sedatives in non-ICU areas on the
incidence of IWS.
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Management of critically ill children also necessitates an interprofessional team
approach. Disagreements within the care team regarding optimal sedation can lead to
inconsistencies in sedation practices that may predispose children to IWS.40 Failure of
interprofessional collaboration, along with variability in training and experience with
sedation management may influence compliance. Poor sedation or weaning protocol
compliance has been shown to increase the incidence of IWS.38
Discussion
To date, the strongest risk factors associated with IWS include duration of therapy
and cumulative dose. Less evidence exists for relationships with age, criticality,
sedation/weaning protocols, and sedation/IWS assessment. This review found few
prospective studies offering data specific to opioid- and/or benzodiazepine-related IWS
risk factors. It was often necessary to search for any mention of associated risk and
extrapolate risk from reported relationships with other variables. The proposed
conceptual model (Figure 2-3) illustrates how the convergence of patient- and processlevel factors within a system context may contribute to IWS.
Studies linking the duration of opioid therapy and IWS proposed that a threshold
of ≥5 days25,27 was predictive of IWS (Figure 2-4). Duration of therapy as a risk factor for
benzodiazepine-related IWS has not been demonstrated, although a 10-day duration30
seems contributory (Figure 2-5). Authors found relationships between cumulative dose of
opioid and/or benzodiazepine and duration of infusion,13,32,34 and cumulative
benzodiazepine doses as risk factors,23 albeit from studies with small sample sizes and
inconsistent results. The observed relationship between dose and duration may be too
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interdependent to determine individual contributions to IWS. For example, a recent study
found that the primary outcome of doubling of daily medication dose (tolerance) was
more likely to occur with infusions lasting >7 days.43
Several studies4,15,25,26 in this review reported IWS accompanying opioid doses
below proposed thresholds, which is potentially attributable to patient-level variability
(e.g., pharmacogenetics, body composition, criticality). Similarly, cumulative dose as a
risk factor for benzodiazepine-related IWS is not adequately supported in the current
literature, as IWS was seen in subjects receiving less than the proposed threshold. Other
factors such as criticality may obscure the relationships among dose, duration and IWS.
Physiologically, as illustrated in the conceptual model, a patient’s therapeutic regimen –
medication doses, duration of therapy, and mode of administration – may all act
synergistically in contributing to the development of tolerance.
Age, size, and dosing weight are interrelated, so the observation that older
children tend to receive higher doses of opioids and benzodiazepines 20 is not surprising.
Furthermore, drug metabolism and excretion, and behavioral responses to discomfort, are
related to a child’s development.44 Studies in this review included different age ranges,
further complicating this picture. More studies with adequate representation of all age
groups are required to demonstrate a more definitive relationship with IWS risk.
Inconsistencies in weaning protocols complicate the analysis of IWS risk, since
abrupt cessation or rapid weaning has been shown to precipitate withdrawal
symptoms.2,8,29,42,45 The lower incidence of IWS in studies with specified weaning
protocols12,29,30,37 may be an indication of the importance of a weaning plan on IWS risk.
Conversely, the fact that IWS occurred in controlled, prospective studies with
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standardized weaning protocols21,33,34 suggests that protocol compliance or failure leading
to IWS must be addressed.
Among opioids, fentanyl has a greater potential for inducing tolerance due to its
shorter half-life and greater opioid receptor affinity.2 More articles in this review reported
IWS in subjects receiving fentanyl than with any other opioid.4,13,15,41 In addition, most of
the studies that reported IWS in patients receiving continuous infusions also administered
fentanyl,4,15,19,34,39,40 which could be the mechanism driving the proposed relationship
between mode of administration and IWS. However, given the prevalence of fentanyl
use, higher administered doses of both opioids and benzodiazepines before the start of
weaning, and longer durations of therapy,1,8 other confounding factors may have
influenced the outcome of IWS.13 This review presents evidence indicating that fentanyl
is more likely to cause IWS than other opioids, but more research is necessary.
Only half of the studies used validated instruments to assess subjects’
IWS.1,4,8,12,13,16,17,21,22,25–30,38,39 Finnegan’s Neonatal Abstinence Score (NAS) tool has not
been validated outside of the neonatal population,46 despite its use in a quarter of the
studies in this review. Establishing the validity and generalizability of other IWS
assessment instruments is challenging, and studies applying validated IWS assessment
tools (e.g. WAT-1,1,8 SOS17,47) are needed. IWS will remain difficult to quantify
objectively until biological markers are available.
Analysis of the literature reveals an evolving discussion of IWS risk in terms of
tolerance- and non-tolerance-related factors. Drug choice, duration of therapy, mode of
administration, and cumulative dose may be substitute measures for tolerance. Age and
criticality are patient-level variables that may constitute risks for IWS independent of
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tolerance. Process-level variables related to clinician decision making, which may be
driven by policies of the larger healthcare system, also contribute to IWS risk but not
tolerance. However, system-level factors have not been consistently recognized or
explored in the existing literature. For example, there is consensus that weaning sedation
requires a time-sensitive titration plan that may not be able to be accomplished in the
PICU when intensive care beds are limited. Providers may need to move patients out of
the PICU as soon as their primary condition has stabilized. In addition, local policies may
not allow the use of some sedatives agents in non-ICU areas, further limiting providers’
ability to maintain a consistent weaning plan in some children. However, none of these
factors were addressed in the articles assembled in this review. Further research is needed
to examine the effect of system-level factors on patients’ risk for developing IWS.
This study has important limitations. Small sample sizes were problematic for
achieving requisite statistical power in several included studies, and the overall quality of
the available data was moderate. In addition, due to the authors’ limitations, articles
published in languages other than English could not be included in this review. This
review was performed according to the PRISMA statement, where applicable, although
an assessment of the risk of bias for each study was not performed. A registered protocol
also was not used in the conduct of this review. A meta-analysis of the selected studies
could not be completed, due to low levels of evidence and significant heterogeneity in the
populations of the included studies.
Conclusion
This is the first systematic review of risk factors associated with IWS in the
critically ill pediatric population that identifies risk factors at the level of the patient,
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process, and system, and describes their relationship with the development of tolerance to
opioids and benzodiazepines. Of all the factors identified, duration of therapy and
cumulative dose are the most predictive of IWS, as has been suggested by other authors.
However, this review particularly highlights the need to further explore process and
system variables, such as sedation/IWS assessment, and protocol adherence. There are
many remaining questions for future studies on risk factors associated with IWS. This
model can be used to guide the design and reporting of future studies on IWS in critically
ill children.
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Figures and Tables
Figure 2-1. Systematic search and selection process
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Figure 2-2. Proportion of subjects with IWS relative to the total number of subjects
among included studies

	
  
Note: Mixed includes studies where the subjects received both opioids and benzodiazepines.
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Figure 2-3. Risk for Iatrogenic Withdrawal Syndrome (IWS). Conceptual model relating
three levels of risk factors for IWS in critically ill children
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Figure 2-4. Cross-study comparison of duration of opioid therapy in opioid-only and
mixed agent (i.e. opioid and benzodiazepine administration) studies, among subjects with
IWS

	
  
27

Reference for 5 day threshold: Katz, Kelly, & Hsi (1994)
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported
in the original studies; the size of each square corresponds to the size of the study sample, with
increasing size for larger samples.
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Figure 2-5. Cross-study comparison of duration of benzodiazepine therapy among
subjects with IWS

	
  
* Duration includes medication taper; ** Reported duration only applies to 9 patients receiving
lorazepam; ***Authors did not specify medication for the listed duration of sedation.
Reference for 10 day threshold: Ista, et al. (2008)30
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported
in the original studies; the size of each square corresponds to the size of the study sample, with
increasing size for larger samples.	
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Figure 2-6. Cross-study comparison of cumulative dose of opioids among subjects with
IWS

	
  
* Provided dose range for total study group, not IWS subjects specifically; ** Values not
calculated in original study.
Reference for 106.7 mg/kg (morphine equivalents) threshold: Arnold, Truog, & Orav (1994)28
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported
in the original studies; the size of each square corresponds to the size of the study sample, with
increasing size for larger samples.
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Figure 2-7. Cross-study comparison of cumulative dose of benzodiazepines among
subjects with IWS

	
  
* Values not calculated in original study; ** Provided dose range for total study group, not IWS
subjects specifically
Reference for 60 mg/kg (midazolam equivalents) threshold: Fonsmark, Rasmussen, & Carl
(1999)23
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported
in the original studies; the size of each square corresponds to the size of the study sample, with
increasing size for larger samples.
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Table 2-1. Detailed search strategy
Medline/PubMed AND CINAHL search strategy for pediatric studies
Search
#1

Terms
ventilator* OR ventilation* OR respirator* OR "Respiration, artificial"[Mesh] OR
"artificial respiration"
#2
weaning OR weaned OR weans OR wean OR discontinue OR terminat*
#3
hypnotic* OR depressant* OR sedat* OR opioid* OR narcotic* OR benzodiazepine*
OR fentanyl OR morphine* OR diazepam OR lorazepam OR midazolam
#4
#1 AND #2 AND #3
Filters: English; Child: birth (manual exclusion of < 2 weeks)-18 years

EMBASE search strategy for pediatric studies
Search
#1

Terms
“ventilator” OR “ventilation” OR “respirator” OR "artificial respiration" OR artificial
ventilation/exp OR assisted ventilation/exp
#2
“weaning” OR “weaned” OR “weans” OR “wean” OR “discontinue” OR “terminate”
OR “termination” [NOTE: No EMTREE term for ventilator weaning]
#3
“hypnotic” OR “depressant” OR “sedative” OR hypnotic sedative agent/exp OR
“opioid” OR “narcotic” OR opiate/exp OR narcotic agent/exp OR “benzodiazepine”
OR benzodiazepine/exp OR fentanyl OR morphine OR diazepam OR lorazepam OR
midazolam
#4
#1 AND #2 AND #3
Limits: English; Child: birth (manual exclusion of < 2 weeks)-18 years
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Table 2-2. Articles on concurrent opioid and benzodiazepine therapy
Study

Site

Sample
Size

Medications

Mode of
Administration

IWS
Assessment

Randomized Control Trial
Bowens et al.
PICU
(2011)29
(US)

N = 78

Fentanyl, midazolam

Continuous

MNWS

Prospective Interventional
Jin et al.
PICU
(2007)12
(Korea)

N = 53

Fentanyl, midazolam

Bolus, continuous

Modified
NAS,
physiologic
s/sx

N = 154

Fentanyl, midazolam,
morphine

Continuous

SOS

N = 126

Not specified
(converted to
morphine & midaz
equivalents)
Not specified
(converted to
morphine & midaz
equivalents)
Fentanyl, midazolam,
morphine

Bolus, continuous

WAT-1

Bolus, continuous

WAT-1, NRS
of RN
clinical
judgment
SBOWC

Prospective Observational
Ista et al.
PICU
(2013)17
(Netherlands)
Franck et al.
PICU
(2012)1
(US)
Franck et al.
(2008)8

PICU
(US)

N = 83

Ista et al.
(2008)30

N = 79

Ducharme et al.
(2005)31

PICU
(Netherlands)
PICU
(Canada)

N = 27

Fentanyl, midazolam

Continuous

Physiologic
s/sx

Franck et al.
(2004)13

CICU
(UK)

N = 15

Fentanyl, lorazepam,
midazolam, morphine

Continuous

OBWS

Meyer & Berens
(2001)21

PICU
(US)

N = 29

Fentanyl, lorazepam,
methadone, morphine

Continuous, PO

NAS

N = 48

Fentanyl, midazolam

Continuous

NAS

N = 15

Fentanyl, midazolam

Continuous,
transdermal

Physiologic
s/sx

N = 20

Fentanyl, morphine

Continuous

N=7

Fentanyl, midazolam

Bolus, continuous

NAS, clinical
judgment of
NICU RNs
and MDs
NAS

Retrospective Chart Review
FernándezPICU
Carrión et al.
(Spain)
(2013)36
Johnson et al.
Academi
(2010)32
c hospital
(US)
Bachiocco et al.
NICU
(2006)22
(Italy)
Tobias
(2006)39

PICU
(US)
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Continuous

Cont’d from previous page
Weaning Method

IWS Incidence (N, %)

Risk Factors

Study Quality

Standard protocol

Low-dose: 9/41 (22%);
High-dose: 4/37 (11%)

Dose; duration

Moderate

Standard protocol

Intervention: 1/21 (5%);
Control: 7/20 (35%)

Dose; sedation
protocol

Moderate

Variable

74/154 (48%)

Age; dose; duration;
drug choice

High

Variable

21/126 (17%)

Dose; duration

Moderate

Variable

53/83 (64%)

Dose; duration

Moderate

Standard protocol

27/79 (34%)

Dose; duration

High

Variable

Not reported

Duration; sedation
protocol

Moderate

Standard protocol

13/15 (87%)

Dose; drug choice

Moderate

Standard protocol

3/29 (10%)

Criticality; dose

Moderate

Variable

24/48 (50%)

Dose; duration

Moderate

Standard protocol

7/15 (47%)

Dose; duration

Moderate

Variable

3/20 (15%)

Criticality

Moderate

Variable

N/A

Dose; mode of
administration

Low
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Cont’d from page 63
Study

Site

Siddappa et al.
(2003)33

PICU
(US)

Jacobs et al.
(2001)18

PICU
(US)

N = 133

Lugo et al.
(2001)34
Fonsmark et al.
(1999)23

PICU

N = 22

Medsurg ICU
(Denmar
k)
PICU
(Canada)

N = 40

Carnevale &
Ducharme
(1997)40
Sheridan et al.
(1994)35
Bergman et al.
(1991)19
Surveys
Jenkins et al.
(2007)20
Twite et al.
(2004)41

Sample
Size
N = 30

Medications
Fentanyl, lorazepam,
midazolam,
methadone,
sufentanil,
remifentanil
Fentanyl, lorazepam,
midazolam, morphine

Mode of
Administration
Continuous

IWS
Assessment
Physiologic
s/sx

Continuous

Clinical
judgment of
PICU RNs
and MDs
Physiologic
s/sx
Physiologic
s/sx

Fentanyl, midazolam,
methadone
Midazolam,
morphine,
pentobarbital

Continuous

N=5

Fentanyl, midazolam,
morphine

Bolus, continuous

Physiologic
s/sx

Burn unit
(US)

N = 24

Midazolam,
morphine

Continuous

ICU
(US)

N = 45

Fentanyl, midazolam

Bolus, continuous

Clinical
judgment of
MDs
Physiologic
s/sx

PICU
(Multisite, UK)

N = 20

24 different agents
reported

Bolus, continuous

Clinical
judgment of
PICU MDs

PICU
(Multisite, US)

N = 35

Fentanyl, lorazepam,
midazolam, morphine

Continuous

Not reported

Bolus, continuous

Legend of abbreviations (listed alphabetically): CICU – Cardiac Intensive Care Unit; CT –
cardiothoracic; D/C – discontinuation; ICU – Intensive Care Unit; MDs – attending physicians;
MNWS – Modified Narcotic Withdrawal Scale (adapted from Finnegan NAS monitoring tool);
NAS – Finnegan’s Neonatal Abstinence Score; NICU – Neonatal Intensive Care Unit; NR – not
reported; NRS – Numeric Rating Scale; OBWS – Opioid Benzodiazepine Weaning Scale; PICU
– Pediatric Intensive Care Unit; PO – oral administration; RCT – randomized controlled trial; RN
– registered nurse; s/sx – signs and symptoms; SBOWC – Sophia Benzodiazepine-Opioid
Withdrawal Checklist; SOS – Sophia Observation withdrawal Symptoms scale; UK – United
Kingdom; US – United States; WAT-1 – Withdrawal Assessment Tool-Version 1
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Cont’d from previous page
Weaning
Method
Standard
protocol
NR

IWS Incidence (N,
%)
10/30 (33%)

Standard
protocol

1/22 (5%)

Abrupt D/C

14/40 (35%)

Variable

N/A

NR

2/24 (8%)

Abrupt D/C

5/45 (11%)

Variable

34/335 (10%)

Variable

65.7% of fellowship
directors

34/133 (26%)

Risk Factors

Study Quality

	
  

Duration; drug
choice
Age

Moderate

	
  

Duration; drug
choice; mode of
administration
Criticality; dose

Moderate

Dose; sedation
protocol; systems
factors
Dose; duration;
mode of
administration
Age; criticality;
mode of
administration

Low

Age; criticality;
dose; drug choice
Drug choice; mode
of administration

N/A
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Moderate

Low

Low
Moderate

N/A

	
  

Table 2-3. Articles on opioid therapy only
Study

Site

Sample
Size

Medications

Mode of
Administration

Withdrawal
Assessment Method

Prospective Interventional
Dominguez et al.
NICU
(2003)25
(US)

N = 19

Fentanyl

Continuous

NAS

Prospective Observational
Fisher et al.
PICU
(2013)16
(US)

N = 26

Fentanyl,
morphine

Bolus,
continuous

WAT-1

Franck et al.
(1998)4

NICU

N = 34

Fentanyl,
morphine

Bolus,
continuous

Opioid weaning
flowsheet (adapted
from NAS)

Dagan et al.
(1994)24

PICU
(Canada)

N =7

Morphine

Continuous

Physiologic s/sx

French & Nocera
(1994)26

PICU
(US)

N = 12

Fentanyl

Bolus,
continuous

NAS

Katz et al.
(1994)27

PICU
(US)

N = 23

Fentanyl

Continuous

NAS

N = 43

Morphine,
methadone

Bolus,
continuous

WAT-1

Retrospective Chart Review
Jeffries et al.
PICU
(2012)38
(Canada)
Lane et al.
(1991)15

PICU
(US)

N = 13

Fentanyl

Continuous

Physiologic s/sx,
clinical judgment of
PICU MDs

Arnold et al.
(1990)28

NICU
(US)

N = 37

Fentanyl,
sufentanil

Continuous

NAS

Legend of abbreviations (listed alphabetically): MDs – attending physicians; NAS – Finnegan’s
Neonatal Abstinence Score; NICU – Neonatal Intensive Care Unit; PICU – Pediatric Intensive
Care Unit; RN – registered nurse; s/sx – signs and symptoms; UK – United Kingdom; US –
United States; WAT-1 – Withdrawal Assessment Tool-Version 1
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Cont’d from previous page
Weaning Strategy

Incidence of IWS

Risk Factors

Study Quality

Standard protocol

10/19 (53%)

Dose; duration

Moderate

Variable

11/25 (44%)

Age; dose; duration;
weaning protocol

Moderate

Standard protocol

Fent: 13/23 (57%);
Morphine: 1/11 (9%)

Dose; drug choice;
duration; mode of
administration

Moderate

No weaning

2/7 (29%)

Dose

Low

Variable

6/12 (50%)

Dose; duration

Low

Standard protocol

13/23 (57%)

Dose; duration

Moderate

Standard protocol

18/43 (42%)

Moderate

Variable

5/13 (39%)

Dose; weaning
protocol; withdrawal
assessment; systems
factors
Age; drug choice;
mode of
administration

Variable

21/37 (57%)

Dose; duration

Low
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Moderate

Table 2-4. Articles on benzodiazepine therapy only
Study

Site

Prospective Interventional
Dominguez et al.
PICU
(2006)37
(US)

Sample
Size

Medications

Mode of
Administration

Withdrawal
Assessment Method

N = 29

Lorazepam

Continuous

Clinical judgment of
PICU MDs

N = 53

Midazolam

Continuous

Clinical judgment of
bedside and research
RNs; non-validated
s/sx checklist

Prospective Observational
Hughes et al.
(1994)14

PICU
(UK)

Legend of abbreviations (listed alphabetically): MDs – attending physicians; PICU – Pediatric
Intensive Care Unit; RN – registered nurse; s/sx – signs and symptoms; UK – United Kingdom;
US – United States
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Cont’d from previous page
Weaning Strategy

Incidence of IWS

Risk Factors

Study Quality

Standard protocol

7/29 (24%)

None

Moderate

Variable

9/53 (17%)

Age; dose

Low
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CHAPTER 3
TOLERANCE, PATTERNS OF WEANING, AND IATROGENIC WITHDRAWAL
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Patterns of sedation weaning in
critically-ill children recovering from acute respiratory failure
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Abstract
Objective: To characterize sedation weaning patterns in typical practice settings among
children recovering from critical illness.
Design: A descriptive secondary analysis of data that were prospectively collected during
the pre-randomization phase (January to July 2009) of a clinical trial of sedation
management.
Setting: Twenty-two pediatric intensive care units across the United States.
Patients: The sample included 145 patients, aged 2 weeks to 17 years, mechanically
ventilated for acute respiratory failure who received ≥5 consecutive days of opioid
exposure.
Measurements and Main Results: Group comparisons were made between patients with
an inconsistent weaning pattern, defined as a ≥20% increase in daily opioid dose after the
start of weaning, and the remaining patients defined as having a consistent weaning
pattern. Demographic and clinical characteristics, opioid tolerance, and iatrogenic
withdrawal symptoms were evaluated. Sixty-six patients (46%) were inconsistently
weaned; 79 patients were consistently weaned. Prior to weaning, inconsistently weaned
patients received higher peak and cumulative doses and longer exposures to opioids and
benzodiazepines, demonstrated more opioid tolerance (39% vs. 24%), and received more
chloral hydrate and barbiturates compared to consistently weaned patients. During
weaning, inconsistently weaned patients assessed for withdrawal had a higher incidence
of Withdrawal Assessment Tool-Version 1 scores ≥3 (85% vs. 46%), and received more
sedative classes compared to consistently weaned patients.
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Conclusions: This study characterizes sedative administration practices for pediatric
patients prior to and during weaning from sedation after critical illness. It provides a
novel methodology for describing weaning in an at-risk pediatric population that may be
helpful in future research on weaning strategies to prevent iatrogenic withdrawal
syndrome.
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Introduction
Most children supported on mechanical ventilation in the pediatric intensive care
unit (PICU) receive opioids and benzodiazepines for sedation during the critical phase of
their illness. Sedation is necessary to help the child mitigate the noxious effects of
invasive therapies [1,2]. An estimated 16% to 35% of mechanically ventilated children
become tolerant to sedative medications while in the PICU [3], defined as diminishing
clinical effectiveness of a drug over the course of treatment [4,5]. However, as children
recover from critical illness sedative medications are discontinued or weaned over time.
The amount of time spent weaning is a balance between keeping a child comfortable and
free from significant withdrawal symptoms that can complicate recovery and minimizing
PICU and hospital lengths of stay [5,6]. Abrupt discontinuation or too rapid weaning of
opioids and/or benzodiazepines in physically dependent children results in iatrogenic
withdrawal syndrome (IWS), a cluster of physiologic signs and symptoms that includes
nervous system hyperirritability, autonomic system dysregulation, gastrointestinal
dysfunction, and motor abnormalities [4,5,7,8].
The evidence informing optimal weaning practices is not robust [1,9]. It is known
that children experiencing longer durations of sedative therapy (>5 to >9 days opioids
[10,11]; >5 days benzodiazepines [12]) and higher cumulative doses (>1.2 mg/kg to >2.5
mg/kg fentanyl [6,10,11,13]; >60 mg/kg midazolam [14]) are more likely to become
tolerant [3,13] and experience IWS [6,10,11,13], which may necessitate a longer duration
of weaning [4,8]. However, data on patient risk for protracted weaning and IWS are more
than a decade old, and the distinction between preweaning and cumulative sedative
exposure is often unclear. Nevertheless, current recommendations for sedation weaning
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include decreasing total doses by 10% to 20% every 24 to 48 hours as tolerated by the
patient and/or sedation substitution with long-acting formulations [4,15]. Published
reports of sedative tapering often exceed these rates [16] with an unclear sequence of
opioid and/or benzodiazepine dose tapering [12,15]. Protocols using methadone weaning
regimens can be problematic because of variable implementation and patient response
[17,18]. Other sedative medications, such as dexmedetomidine, clonidine, and ketamine,
have been introduced but their contribution to successful weaning is unknown.
Given that there are now more sedative agents and nuanced approaches to
sedation therapy, it is worth re-examining our understanding of which patients can or
cannot tolerate rapid weaning, especially since the optimal approach to sedative titration
remains elusive. Moreover, the pattern and time course of opioid and benzodiazepine
weaning in children recovering from critical illness remains poorly characterized.
Clinician approaches to weaning may vary substantially [16] even in the presence of
standardized sedation protocols. Greater understanding of the different patterns of
weaning and their association with specific patient characteristics, such as clinical signs
of IWS, may expedite the weaning process in at-risk patients. The purpose of this study
was to characterize patterns of weaning in the context of current practice and to compare
the characteristics of children with different patterns of weaning during recovery from
critical illness.
Materials and Methods
Design: This study was a secondary analysis conducted on prospective data from
the baseline, pre-randomization phase of the Randomized Evaluation of Sedation
Titration fOr Respiratory FailurE (RESTORE) clinical trial. RESTORE was a multicenter
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study designed to test a sedation management protocol in critically-ill pediatric patients
with acute respiratory failure, defined as acute lung disease involving the airway and/or
lung parenchyma [19]. During the baseline, pre-randomization phase (January to July
2009), all enrolled patients received usual care in 22 participating centers, but each PICU
implemented the same pediatric-specific assessment tools for pain, sedation and IWS
[20,21]. Sedation management was otherwise unrestricted. Institutional Review Board
approval was obtained from each participating site. Consent for data collection was
obtained from the parents and/or legal guardians of each patient.
Study population: Patients aged 2 weeks (≥42 weeks postmenstrual age) to 17
years were included if they were intubated and mechanically ventilated for acute
respiratory failure [19]. This analysis was restricted to baseline phase patients exposed to
≥5 consecutive days of opioids from continuous infusions, scheduled intermittent, or as
needed bolus doses; who completed opioid weaning within the 28-day data collection
period without transfer or redirection of care; and who survived to hospital discharge.
This restriction allowed for the full evaluation of a patient’s completed course of sedation
therapy and the identification of individual patient patterns of weaning from sedation.
Variables and measures: Demographic and clinical data collected at enrollment
included patient age, gender, race, ethnicity, Pediatric Cerebral Performance Category
(PCPC) and Pediatric Overall Performance Category (POPC) [22], baseline verbal
ability, mortality risk (PRISM III-12) [23], reason for intubation, pediatric acute
respiratory distress syndrome (PARDS) criteria [24], and past medical history. The PCPC
and the POPC are measures developed to describe cognitive impairment and functional
morbidity in children, respectively [25]. Each measure is a six-point scale of increasing
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disability ranging from normal function to death [22,25]. The Pediatric Risk of Mortality
(PRISM) III-12 score is a third-generation tool for estimating risk of PICU mortality
based upon a patient’s age, operative status, and values for 17 physiologic variables
measured within the first 12 hours after PICU admission [23]. Higher scores indicate
greater physiologic instability and higher risk of mortality. PARDS classifications were
defined according to published criteria from the Pediatric Acute Lung Injury Consensus
Conference Group [24]. Hospital course variables included lengths of mechanical
ventilation, PICU stay, and hospital stay.
Medication data included receipt of neuromuscular blockade, cumulative and
peak daily opioid dosage (in morphine equivalents per kg of body weight), cumulative
and peak daily benzodiazepine dosage collected to the end of opioid weaning (in
midazolam equivalents per kg of body weight), and administration of any other sedative
medications (e.g., chloral hydrate, clonidine, dexmedetomidine, ketamine, pentobarbital,
phenobarbital, and propofol). Daily and cumulative sedative medication doses were
compared using standard equivalencies [19]. Specifically, morphine equivalent
conversion factors to equal 1mg morphine sulfate were as follows: 15µg remifentanil;
15µg fentanyl; 0.15mg hydromorphone; and 0.3mg methadone. Midazolam equivalent
conversion factors to equal 1mg midazolam were: 0.2mg clonazepam; 0.3mg lorazepam;
and 2mg diazepam. Sedative data were collected daily from endotracheal intubation,
initiation of assisted breathing for patients with tracheostomies, or PICU admission for
patients intubated at an outside hospital (Day 0) until 72 hours after their last opioid dose,
hospital discharge, or Day 28 (whichever occurred first). Thresholds for opioid and
benzodiazepine exposure from previous investigations of IWS were examined
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[6,11,13,14]. Tolerance to the sedative effect of opioids was defined as a doubling of the
Day 2 opioid dose prior to the start of weaning, an adaptation of Anand et al. [3] who
defined tolerance as a doubling of the initially effective dose received during the first 24
hours of therapy. Using Day 2 data provided a more conservative approach to quantifying
tolerance in cases where subjects may have been started on sub-optimal initial doses and
required titration to achieve clinical effect.
Patients were assessed for signs of IWS using the Withdrawal Assessment Tool –
Version 1 (WAT-1) [20,26]. The WAT-1 is an 11-item (12-point) instrument that
includes a review of the patient’s medical record for the past 12 hours; direct observation
of the patient for 2 minutes pre-stimulation; patient response to stimulation [27]; and
assessment of post-stimulus recovery [26]. WAT-1 scoring was to be completed at least
every 12 hours while the patient was in the PICU, and at least daily while in the hospital,
from the day opioid weaning commenced until 72 hours after the patient received the last
opioid dose. The highest daily WAT-1 score was used in analyses, with scores ≥3 being
used as a validated cutoff for IWS from previous studies [20,26]. No recommendations
were provided for patient management based on WAT-1 score during the baseline period.
Weaning pattern: Line graphs illustrating daily opioid and benzodiazepine doses
and WAT-1 scores over the study period were constructed for each patient (L.A.A). Two
investigators (L.S.F. and M.A.Q.C.), blind to the clinical characteristics of each patient,
independently reviewed each patient’s graph to make a preliminary determination
regarding each patient’s weaning pattern. These observations were then used to construct
a decision-making algorithm (K.M.B.) for verifying, assigning, or reassigning the
patient’s clinician-reported start of opioid weaning (Figure 3-1). Assignment of the start
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of opioid weaning was necessary for patients with missing data. In addition, the clinicianreported start of opioid weaning may have been unreliable in cases where there was >2
day difference between the start of weaning and the day of peak dose. The start of opioid
weaning was reassigned if (1) the clinician-reported start of weaning occurred >2 days
before a peak opioid dose and/or (2) methadone was started >2 days before the clinicianreported start of weaning.
Once a patient’s start of weaning was verified, a weaning pattern was assigned.
An inconsistent pattern of weaning was assigned to those patients with an irregular
pattern of weaning that included a 20% or greater increase in the total daily opioid dose at
any time during the weaning period. A consistent pattern of weaning was assigned to the
remaining patients.
Data analysis: Descriptive statistics were calculated, including means, standard
deviations, medians, and interquartile ranges for continuous variables, and frequency
counts and percentages for categorical variables. Group comparisons were made between
patients with an inconsistent weaning pattern and those with a consistent weaning pattern.
Logistic, cumulative logit, linear, and proportional hazards regression, controlling for site
as a cluster variable using generalized estimating equations, were used to analyze binary,
ordinal, log-transformed continuous, and time-to-event variables, respectively. Analyses
were performed using SAS (version 9.4, SAS Institute, Cary, NC) and R (version 3.1.1,
The R Foundation for Statistical Computing, Vienna, Austria).
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Results
Patient characteristics: Of 308 patients enrolled in the baseline, pre-randomization
phase of the RESTORE clinical trial, 186 patients experienced five or more consecutive
days of opioid administration. An additional 36 patients were excluded because weaning
was not complete by the end of the 28-day study period, one patient was lost to follow-up
because of transfer to an outside institution, and four patients were non-survivors. The
final sample included 145 patients.
The median opioid start of weaning was 6 days (interquartile range [IQR]: 5-8
days), and 66 patients (46%) were inconsistently weaned. The start of opioid weaning
occurred later for patients with an inconsistent pattern of weaning compared to patients
with a consistent pattern of weaning (median; IQR: Day 6; 5-9 vs Day 5; 5-7; P=0.006).
Figure 3-2 illustrates graphs of representative patients with consistent and inconsistent
patterns of weaning.
Patient characteristics are shown in Table 3-1. There were no significant
differences in baseline demographic or clinical characteristics between patients with
inconsistent and consistent patterns of weaning. Patients with an inconsistent pattern of
weaning experienced a longer duration of mechanical ventilation and PICU and hospital
lengths of stay when compared to patients who were weaned consistently. Patients with
an inconsistent pattern of weaning also had higher total cumulative opioid (median; IQR:
35.7 mg/kg; 17.4-61.2 vs 16.5 mg/kg; 7.4-25.5; P<0.001) and benzodiazepine doses (28.3
mg/kg; 11.2-65.0 vs 12.8 mg/kg; 5.7-22.2; P<0.001) than patients with a consistent
pattern of weaning.
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Preweaning exposure: Characteristics of opioid and benzodiazepine exposure in
the preweaning period are shown in Table 3-2. The majority of patients in both groups
received fentanyl and midazolam as their primary opioid and benzodiazepine agents. In
the preweaning period, patients with an inconsistent pattern of weaning received higher
preweaning daily peak and cumulative doses of opioids and benzodiazepines and had
longer durations of exposure to opioids and benzodiazepines. Patients with an
inconsistent weaning pattern were also more likely to have developed tolerance to
opioids, and to have received a total midazolam dose >60 mg/kg prior to the start of
weaning. Inconsistently weaned patients were more likely to have received chloral
hydrate and barbiturates. There were no significant differences between groups in the
number of patients receiving methadone, clonidine, dexmedetomidine, ketamine, or
propofol prior to the start of opioid weaning.
Exposure during weaning: Characteristics of opioid and benzodiazepine exposure
during weaning are shown in Table 3-3. The percent decrease in daily opioid dose over
the first 24 and 48 hours after the initiation of weaning was lower among patients with
inconsistent patterns of weaning. Inconsistently weaned patients received more opioid
boluses and received boluses for significantly more days during the weaning period. A
greater proportion of patients with an inconsistent pattern of weaning received
methadone, clonidine, dexmedetomidine, chloral hydrate, and barbiturates during the
weaning period. One hundred twelve (77%) patients were assessed for withdrawal
symptoms using the WAT-1. More patients with an inconsistent pattern of weaning had
WAT-1 assessments performed during the weaning period, had WAT-1 scores ≥3, and
had higher peak WAT-1 scores. Among patients with WAT-1 assessments, tolerance to
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opioids was observed more frequently in patients who ever had WAT-1 scores ≥3,
compared to patients who always scored <3 (37% vs 19%; P=0.02).
Discussion
This study is the first multicenter analysis of patterns of sedation weaning among
children recovering from critical illness. We used a novel algorithm to identify the start
of weaning with a graphical approach to plot changes in sedative dosing with
corresponding withdrawal assessments for each patient, which allowed us to classify two
patterns of weaning: consistent and inconsistent. The inconsistent weaning pattern was
associated with higher (preweaning and overall) cumulative and peak doses and longer
preweaning exposures of opioids and benzodiazepines, as well as longer lengths of
hospital stay. Higher WAT-1 scores associated with IWS were also seen in inconsistently
weaned patients with completed assessments.
Our findings align with previous research, which showed that higher cumulative
and peak doses of opioids and benzodiazepines and longer exposures are associated with
IWS [6,10-13,16,20,28]. However, our data are the first to quantify their associations
with an inconsistent weaning pattern. While intuitive, these findings suggest that current
weaning practices should be more critically examined, not only for the rate of dose
reductions but also for consistency. Of note, our two patterns of weaning could not be
differentiated by previously published threshold doses of fentanyl that have been
associated with IWS. These published thresholds included sedative doses received after
the start of weaning [6,10,11], a criterion that limits their prognostic utility for weaning
outcomes.
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In this study, more patients with an inconsistent pattern of weaning met criteria
for opioid tolerance. Typically, the focus of opioid tolerance is placed on the escalation of
sedation therapy and not necessarily on sedation weaning. Only one previous study
reported using a standard definition of opioid tolerance when describing the weaning
process [3], which was adapted for this analysis. Future studies can apply this easily
computed definition of opioid tolerance, that is, a doubling of the Day 2 opioid dose to
achieve the same therapeutic effect over the acute preweaning phase of illness, when
planning how best to wean patients from sedation.
During the first 24 and 48 hours of weaning, consistently weaned patients
tolerated a greater percent drop in their daily opioid dose. In addition, our data show
wide variation in the percent drop experienced by patients during opioid weaning, even
when unit-based weaning protocols were reported to be in place. Patients with an
inconsistent pattern of weaning received significantly more opioid rescue bolus doses for
a greater number of days during the weaning period, beginning with the day of the start
of weaning. This result may indicate that signs of IWS were first observed soon after the
start of weaning.
Examination of WAT-1 scores showed that more inconsistently weaned patients
with assessments had peak WAT-1 scores ≥3. It is interesting to note that patients with
inconsistent patterns of weaning experienced greater frequency and severity of WAT-1
scores despite receiving significantly more doses of methadone, clonidine,
dexmedetomidine, chloral hydrate, and barbiturates during the weaning period.
This study has some limitations, the most significant of which is that the findings
cannot offer evidence for causation. The question of whether inconsistent weaning
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patterns are the outcome of preweaning risk factors or a contributory cause of higher
WAT-1 scores and more intensive or protracted weaning remains unanswered. In
particular, not all patients were assessed for IWS, which may have caused an
ascertainment bias in the observed association between inconsistent weaning and IWS.
Without a complete picture of benzodiazepine weaning in this dataset or a definition of
benzodiazepine tolerance, it is impossible to draw conclusions about tolerance to
benzodiazepines among patients in this study. It is possible that patients became tolerant
to both opioids and benzodiazepines, especially since more inconsistently weaned
patients received preweaning benzodiazepine doses >60 mg/kg, a threshold associated
with IWS [14]. As in previous studies [7,26], it is impossible to parse the effects of these
medications, since most patients received both concurrently. Finally, the available data
offers little insight into the clinical practices or environment in which children were
undergoing recovery and weaning, or the effects of either sedation therapy or the
environment on restorative sleep, both of which may have been contributory to increased
sedative needs in certain patients [29,30]. These considerations will require further
research.
Conclusion
This study provides further characterization of the clinical profiles of pediatric
patients during weaning from sedatives after critical illness. Using baseline, preintervention data allowed this study an unrestrained view of current practices in sedation
management and weaning in PICUs of varying size and geographic location. Our
findings suggest that weaning is consistent and uncomplicated among patients who
receive lower preweaning medication doses and fewer days of sedative exposure. By
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contrast, inconsistent weaning is associated with opioid tolerance and possibly worse
clinical outcomes, including higher incidence and severity of withdrawal symptoms and
longer lengths of stay. Further research is needed to improve the practice of opioid and
benzodiazepine weaning in pediatric patients, which may be strengthened by the
application of the methods and operational definitions described here.
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Figures and Tables
Figure 3-1. Start of weaning decision algorithm

Note: The algorithm assigned the start of opioid weaning for 42 patients (29%) missing data on
the clinician-reported start of weaning. For the remaining 103 patients, the clinician-reported
start of weaning was verified by the algorithm for 78 patients (76%) and reassigned for 25
patients (24%).
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Figure 3-2. Opioid weaning patterns

Representative graphs of daily opioid and benzodiazepine doses among patients with consistent
(A) and inconsistent (B) patterns of opioid weaning. Note: The first vertical line marks the day of
the peak opioid dose, while the second vertical line represents the start of the opioid weaning
period.

85

Table 3-1. Patient characteristics by pattern of weaning
Variable
Baseline Characteristics
Age at PICU admission
Median (IQR) – years
2 weeks to 1.99 years – no. (%)
2.00 to 5.99 years
6.00 to 17.99 years
Female – no. (%)
Non-Hispanic white – no./total no. (%)
Baseline PCPC=1 – no. (%)b
Baseline POPC=1 – no. (%)b
Able to verbally communicate pain at baseline –
no./total no. (%)c
PRISM III-12 score – median (IQR)
Percent risk of mortality based on PRISM III-12
score – median (IQR)
Primary reason for intubation – no. (%)
Pneumonia
Bronchiolitis
Acute respiratory failure related to sepsis
Asthma or reactive airway disease
Aspiration pneumonia
Other
PARDS based on Day 1 OI or OSI – no. (%)d
At risk (OI <4.0 or OSI <5.0)
Mild (OI 4.0-7.9 or OSI 5.0-7.4)
Moderate (OI 8.0-16.0 or OSI 7.5-12.3)
Severe (OI >16.0 or OSI >12.3)
Neuromuscular blockade for the entire duration of
Days 0 to 2 – no. (%)
Any past medical history – no. (%)
Prematurity (<36 weeks post-menstrual age)
Asthma (prescribed bronchodilators or steroids)
Seizure disorder (prescribed anticonvulsants)
Neurologic/neuromuscular disorder which places
patient at risk for aspiration
Cancer (current or past diagnosis)
Known chromosomal abnormality
Hospital Course
Duration of mechanical ventilation – days, median
(IQR)
PICU length of stay – days, median (IQR)
Hospital length of stay – days, median (IQR)

Consistent
Wean (N=79)

Inconsistent
Wean (N=66)

P Valuea

2.0 (0.4-8.3)
40 (51)
11 (14)
28 (35)
45 (57)
45/76 (59)
62 (78)
61 (77)

1.4 (0.3-4.9)
37 (56)
15 (23)
14 (21)
33 (50)
43/64 (67)
48 (73)
45 (68)

0.32
0.16

31/44 (70)
6 (2-12)

29/34 (85)
6 (3-12)

<0.001
0.44

2 (1-12)

3 (1-13)

0.46
0.58

31 (39)
23 (29)
6 (8)
5 (6)
4 (5)
10 (13)

28 (42)
16 (24)
7 (11)
5 (8)
1 (2)
9 (14)

28 (35)
24 (30)
18 (23)
9 (11)

23 (35)
17 (26)
19 (29)
7 (11)

3 (4)

5 (8)

0.40

10 (13)
12 (15)
11 (14)

5 (8)
10 (15)
6 (9)

0.14
0.96
0.46

8 (10)
1 (1)
3 (4)

7 (11)
5 (8)
4 (6)

0.83
0.03
0.52

0.49
0.52
0.28
0.11

0.76

9.1 (6.3-11.9)
5.9 (4.7-8.2)
9.3 (6.9-12.7)
14 (10-20)

12.8 (9.5-17.0)
21.5 (16-26)

<0.001
<0.001
<0.001

IQR, interquartile range; OI, oxygenation index; OSI, oxygen saturation index; PARDS, pediatric
acute respiratory distress syndrome; PCPC, Pediatric Cerebral Performance Category; PICU,
pediatric intensive care unit; POPC, Pediatric Overall Performance Category; PRISM III-12,
Pediatric Risk of Mortality III score from first 12 hours in the PICU.
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a

P values for the comparison of patients with consistent vs. inconsistent weaning patterns were
calculated using linear, cumulative logit, logistic, and proportional hazards regression accounting
for site as a cluster variable using generalized estimating equations for log-transformed
continuous, ordinal, binary, and time-to-event variables, respectively.
b
PCPC and POPC range from 1 to 6, with higher categories indicating greater impairment.
c
Able to verbally communicate pain at baseline includes only patients aged 16 months and older.
d
Oxygenation index (OI) was calculated as [(FIO2 × mean airway pressure)/PaO2 × 100]. When
an arterial blood gas was not available, SpO2 was used to estimate PaO2 in order to calculate
oxygen saturation index (OSI) [(FIO2 × mean airway pressure)/SpO2 × 100]. Lower scores reflect
better oxygenation.
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Table 3-2. Opioid and benzodiazepine exposure pre-opioid weaning by pattern of
weaning
Variable
Primary opioid agent preweaning – no. (%)b
Fentanyl
Morphine
Hydromorphone
Opioid exposure preweaning – mg/kg, median
(IQR)d
Peak daily dose
Cumulative dose
Cumulative dose – morphine only
Cumulative dose – fentanyl only, mcg/kg
Exposure days – median (IQR)
Primary benzodiazepine agent pre-opioid
weaning – no. (%)b,e
Midazolam
Lorazepam
None
Benzodiazepine exposure pre-opioid weaning
– mg/kg, median (IQR)e
Peak daily dose
Cumulative dose
Exposure days – median (IQR)
Tolerance
Doubling of Day 2 opioid dose pre-opioid
weaning – no. (%)
Thresholds pre-opioid weaning – no. (%)
Total fentanyl >2.5 mg/kg or >9 days11
Total fentanyl >1.6 mg/kg or >5 days13
Total fentanyl >1.2 mg/kg6
Total midazolam >60 mg/kge,14
Other sedatives pre-opioid weaning – no. (%)
Methadone
Clonidine
Dexmedetomidine
Ketamine
Chloral hydrate
Propofol
Barbiturates
Number of sedative classes received pre-opioid
weaning – median (IQR)g
1 – no. (%)
2
3
4-7

P Valuea

Consistent
Wean (N=79)

Inconsistent
Wean (N=66)

58 (73)
21 (27)
0

47 (71)
18 (27)
1 (2)

3.4 (1.7-5.7)
13.4 (6.4-21.7)
0.1 (0-1.3)
187.8 (3.1-319.0)
5 (5-6)

5.0 (2.6-7.9)
19.8 (9.7-39.1)
0.4 (0-2.6)
196.7 (16.2-433.4)
6 (5-9)

59 (75)
18 (23)
2 (3)

51 (77)
15 (23)
0

2.7 (1.5-4.9)
9.6 (4.6-17.6)
5 (5-6)

4.1 (1.6-7.3)
15.4 (6.1-38.5)
6 (5-9)

0.005
<0.001
<0.001

19 (24)

26 (39)

0.01

6 (8)
23 (29)
0
0

9 (14)
27 (41)
4 (6)
11 (17)

0.33
0.14
0.27
0.005

6 (8)
0
12 (15)
11 (14)
7 (9)
10 (13)
3 (4)

10 (15)
1 (2)
16 (24)
10 (15)
14 (21)
3 (5)
9 (14)

0.09
1.0
0.17
0.92
0.01
0.11
0.04

2 (2-3)
2 (3)
46 (58)
22 (28)
9 (11)

2 (2-3)
0
34 (52)
18 (27)
14 (21)

0.07

0.94c

0.006
0.004
0.04
0.30
<0.001
0.52f

IQR, interquartile range.
a
P values for the comparison of patients with consistent vs. inconsistent weaning patterns were
calculated using logistic, linear, and proportional hazards regression accounting for site as a
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cluster variable using generalized estimating equations for binary, log-transformed continuous,
and time-to-event variables, respectively. Where there was a zero count in the consistent wean
group, the P value was calculated with the use of a stratified exact test with adjustment for site.
b
Primary opioid agent during the preweaning period was defined as the opioid administered via
continuous infusion. If no opioid or more than one opioid was administered via continuous
infusion, primary opioid agent was defined as the opioid administered on the highest number of
study days. If fentanyl and morphine were administered on the same number of days, primary
opioid agent was defined as the opioid contributing the highest morphine equivalents. Primary
benzodiazepine during the pre-opioid weaning period was assigned similarly. If midazolam and
lorazepam were administered on the same number of days, primary benzodiazepine agent was
defined as the benzodiazepine contributing the highest midazolam equivalents.
c
This P value compares primary agent morphine vs. fentanyl.
d
Opioid doses were calculated as morphine equivalents in mg/kg. Opioids (morphine
equivalents) include morphine (1), fentanyl (0.015), methadone (0.3), enteral codeine (20),
hydromorphone (0.15), enteral oxycodone (3), and remifentanil (0.015).
e
Benzodiazepine data was collected until study discharge, which was based on the end of opioid
exposure; thus patients may have still been receiving benzodiazepines at study discharge.
Benzodiazepine doses were calculated as midazolam equivalents in mg/kg. Benzodiazepines
(midazolam equivalents) include midazolam (1), clonazepam (0.2), lorazepam (0.3), and
diazepam (2). Excludes 9 patients (6 consistent, 3 inconsistent) who did not wean from
benzodiazepines.
f
This P value compares primary agent midazolam vs. lorazepam.
g
Different sedative classes include opioids, benzodiazepines, alpha2-adrenergic agonists,
ketamine, chloral hydrate, propofol, and barbiturates.
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Table 3-3. Opioid and benzodiazepine exposure during opioid weaning by pattern of
weaning
Variable

Consistent
Wean (N=79)

Inconsistent
Wean (N=66)

P Valuea

0.9 (0.1-2.7)
1.5 (0.1-4.3)
2 (1-5)

3.0 (1.0-5.6)
11.5 (3.9-19.9)
10.5 (8-13)

<0.001
<0.001
<0.001

1.1 (0.1-2.6)
1.5 (0.3-4.5)

2.3 (1.2-5.5)
9.0 (2.7-19.6)

<0.001
<0.001

47 (0-100)

24 (–10-57)

<0.001

82 (13-100)

42 (–2-81)

0.02

50 (63)

57 (86)

0.003

1 (1-2)

3 (2-5)

<0.001

15 (19)
1 (1)
14 (18)
4 (5)
3 (4)
6 (8)
2 (3)

37 (56)
8 (12)
23 (35)
5 (8)
7 (11)
7 (11)
6 (9)

<0.001
0.004
0.002
0.64
0.04
0.64
0.002

2 (1-3)
7 (9)
13 (16)
39 (49)
14 (18)
6 (8)

2 (2-3)
0
4 (6)
31 (47)
16 (24)
15 (23)

<0.001

50 (63)
23/50 (46)
2 (1-5)

62 (94)
53/62 (85)
5 (4-6)

<0.001
<0.001
<0.001

Opioid exposure during weaning – mg/kg,
median (IQR)
Peak daily doseb
Cumulative doseb
Exposure days – median (IQR)
Benzodiazepine exposure during opioid weaning
– mg/kg, median (IQR)
Peak daily dosec
Cumulative dosec
Percent drop in daily opioid dose from start of
wean to next day – median (IQR)d
Percent drop in daily opioid dose from start of
wean to 2 days later – median (IQR)d
Received opioid bolus doses during weaning –
no. (%)
Number of days patient received opioid bolus
doses – median (IQR)
Other sedatives during opioid weaning – no.
(%)e
Methadone
Clonidine
Dexmedetomidine
Ketamine
Chloral hydrate
Propofol
Barbiturates
Number of sedative classes received during
opioid weaning – median (IQR)
0, no. (%)
1
2
3
4-7
WAT-1 assessments performed during opioid
weaning – no. (%)
WAT-1 ever ≥ 3 – no./total no. (%)
Peak WAT-1 score – median (IQR)

IQR, interquartile range; WAT-1, Withdrawal Assessment Tool – Version 1.
a
P values for the comparison of patients with consistent vs. inconsistent weaning patterns were
calculated using linear, proportional hazards, and logistic regression accounting for site as a
cluster variable using generalized estimating equations for log-transformed continuous, time-toevent, and binary variables, respectively. Percent drop variables were not log-transformed due to
negative values.
b
Opioid doses were calculated as morphine equivalents in mg/kg. Opioids (morphine
equivalents) include morphine (1), fentanyl (0.015), methadone (0.3), enteral codeine (20),
hydromorphone (0.15), enteral oxycodone (3), and remifentanil (0.015).
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c

Benzodiazepine data was collected until study discharge, which was based on the end of opioid
exposure; thus patients may have still been receiving benzodiazepines at study discharge.
Benzodiazepine doses were calculated as midazolam equivalents in mg/kg. Benzodiazepines
(midazolam equivalents) include midazolam (1), clonazepam (0.2), lorazepam (0.3), and
diazepam (2).
d
Excludes 2 consistently weaned patients who started weaning on day 5 and were study
discharged that day.
e
Different sedative classes include opioids, benzodiazepines, alpha2-adrenergic agonists,
ketamine, chloral hydrate, propofol, and barbiturates.
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Abstract
Rationale: Sedation use in pediatric critical illness is associated with iatrogenic
withdrawal syndrome during recovery. Little is known about risk factors for iatrogenic
withdrawal beyond sedative dose and exposure time.
Objectives: To create a predictive model of patient, process and system risk factors for
iatrogenic withdrawal in critically ill pediatric patients who received ≥5 days of sedation.
Methods: Secondary analysis of prospective data from a clinical trial of nurse-led, goaldirected sedation management. Logistic regression with generalized estimating equations
to account for clustering by site was used to evaluate risk factors for iatrogenic
withdrawal.
Measurements and Main Results: Iatrogenic withdrawal was defined as having at least
two Withdrawal Assessment Tool-1 scores ≥3 after the start of opioid weaning. Eligible
subjects with iatrogenic withdrawal (544/1157; 47%) were younger and more likely to
have pre-existing cognitive or functional impairment. Subjects with iatrogenic
withdrawal received higher sedative doses and longer exposure periods. In multivariable
analyses, significant predictors of iatrogenic withdrawal included younger age (OR 2.73,
p<0.001), pre-existing cognitive impairment (OR 1.98, p<0.001), higher preweaning
mean daily opioid dose (OR 1.39, p<0.001), longer duration of sedation (OR 1.07,
p=0.046), receipt of three or more preweaning sedative classes (OR 1.39, p<0.001),
higher nursing workload (OR 1.68, p=0.004) and receiving care at sites with higher
proportions of 1:1 nurse staffing (OR 1.15, p=0.002).
Conclusions: Iatrogenic withdrawal syndrome is common in children recovering from
critical illness and several risk factors are predictive. High-risk patients could be
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identified before starting weaning to better prevent iatrogenic withdrawal among at-risk
patients.
Key words: Opioid; benzodiazepine; sedation; WAT-1; RESTORE
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Introduction
Although opioids and benzodiazepines are routinely used to achieve analgesia and
sedation in critically ill pediatric patients, they may also cause untoward effects. In
particular, iatrogenic withdrawal syndrome (IWS) can cause discomfort for patients,
increased sedation exposure and prolonged duration of mechanical ventilation and
lengths of stay.1,2 IWS is a constellation of signs and symptoms spanning three
physiologic domains – autonomic dysfunction, gastrointestinal disturbances and
neurologic and motor abnormalities – that manifest following rapid weaning or abrupt
cessation of sedation therapy in physically dependent patients.1,3,4 Up to 57% of critically
ill children in the pediatric intensive care unit (PICU) who receive opioids or
benzodiazepines may exhibit signs and symptoms of IWS,5–7 a figure that increased to
nearly 80% in a cohort of infants who had undergone extracorporeal membrane
oxygenation (ECMO) or cardiac surgery.8
To date, the majority of research on IWS has focused on characterizing its signs
and symptoms3,4,9,10 and elucidating its association with threshold sedative
exposures,5,7,11–14 such as duration of opioid or benzodiazepine therapy exceeding five
days7,13 and cumulative doses greater than 1.6 mg/kg of fentanyl5,7 or 60 mg/kg of
midazolam.14 Yet a clinical profile of the patient at risk for IWS is still lacking. Most
previous studies have been limited by single center, retrospective designs and/or small
samples. Younger12,15,16 or female15 patients with a greater severity of illness,15 including
neurologic involvement,17,18 may be more likely to experience IWS. However, these
findings have been inconsistent across published reports,19,20 at least in part due to a lack
of standardization in defining and assessing IWS.21
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Sedation management in the PICU occurs within a unique context that may also
influence the development of IWS; however, little research has evaluated the process of
sedation therapy or system-level determinants of related outcomes. For example,
although most clinicians recognize the need to gradually wean patients from sedation
therapy in order to prevent IWS,22,23 variation exists in the medications and doses used
during sedation and weaning.12,24,25 Adherence to standardized sedation protocols
including weaning algorithms and assessments for IWS is less than ideal,26,27 which may
be a consequence of clinician factors27–30 or workflow constraints in busy PICUs.31 Little
is known about system-level factors that may prevent the development of IWS in
critically ill children.
These gaps have resulted in a limited understanding of why children continue to
experience IWS despite the implementation of protocols to prevent it.6,17,26,32 We have
proposed a conceptual model illustrating the potential contributions of different levels of
risk factors that impact a critically ill child’s risk for experiencing IWS during recovery
in the PICU.21 The purpose of this study was to apply this framework in generating a
predictive model of risk factors for IWS at the levels of the patient, the process and the
healthcare system. A comprehensive profile of the at-risk patient may enable primary
prevention of this iatrogenic complication, including potential restructuring of processes
and systems of care in order to optimize sedation therapy for children in the PICU.
Methods
Data source: This study was a secondary analysis of data from the Randomized
Evaluation of Sedation Titration fOr Respiratory FailurE (RESTORE) clinical trial.
RESTORE was a multicenter cluster randomized trial testing the impact of a nurse-led,
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goal-directed sedation management protocol on length of mechanical ventilation in
critically ill pediatric patients with acute respiratory failure.6 Subjects were enrolled at 31
sites from June 2009 to December 2013. Consent for prospective data collection was
obtained from the subjects’ parents and/or legal guardians, and the institutional review
board at each site approved the RESTORE study protocol.
Study population: Patients aged 2 weeks (≥42 weeks postmenstrual age) to 17
years were enrolled in the RESTORE trial if they were intubated and mechanically
ventilated for acute respiratory failure. Detailed inclusion and exclusion criteria are
published elsewhere.6 Eligible subjects for this secondary analysis included subjects from
both the control and intervention groups who had ≥5 consecutive days of opioid exposure
from continuous infusions, scheduled intermittent or as needed bolus doses. We excluded
subjects who did not complete their course of sedative weaning within 28 days (i.e., nonsurvivors, transfers and study withdrawals).
Variables and measures: The primary outcome of IWS was defined as two or
more Withdrawal Assessment Tool-1 (WAT-1) scores ≥3 after the start of opioid
weaning. The WAT-1 is an 11-item (12-point) instrument that screens for signs and
symptoms of opioid- and benzodiazepine-related IWS.4,9 Per protocol, subjects with ≥5
days of opioid therapy were assessed at least twice daily in the PICU, and at least daily
while in the hospital, from the start of opioid weaning until 72 hours after the last opioid
dose. A one-time WAT-1 score ≥3 has excellent sensitivity (87%) and specificity (88%)
for detection of IWS.4 Requiring more than one WAT-1 score ≥3 was a conservative
approach to avoid inclusion of false positives from subjects with isolated symptoms
unrelated to IWS.
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Data were collected daily from endotracheal intubation (Day 0) until 72 hours
after the last opioid dose, hospital discharge or Day 28 (whichever occurred first).
Medication data included daily dose and route of all sedative medications, until the start
of opioid weaning. Patient- and process-level variables were defined as in the primary
publication6 or according to operational definitions included in the online supplement.
System-level variables were drawn from each site’s self-reported pre-randomization
organizational assessment and the case report forms from each enrolled subject. Each
subject was assigned values for the system-level variables from their site, with the
exception of nursing workload. The Nine Equivalents of nursing Manpower use Score
(NEMS)33 was calculated daily for each patient; possible scores ranged from 0 to 56, with
higher scores representing increasing nursing workload. Median preweaning scores
calculated for each subject were used for analysis.
Analysis: Subjects meeting eligibility criteria were dichotomized based on WAT1 scores. Potential predictors of interest (Supplemental Table 4-5) were explored for
differences between groups. Variance within and between centers was accounted for
using generalized estimating equations with an independent working correlation structure
and robust sandwich variance estimator. Site-level variables were weighted by the inverse
variance of each site’s IWS rate, then Pearson correlations (for continuous predictors)
and linear regressions (for binary predictors) were used to evaluate associations with the
proportion of subjects with IWS. Log-transformations were used as necessary for nonnormally distributed variables. An a priori threshold of p <0.2 was set for variables from
bivariate analyses to be considered in the next stage of analysis. Multivariable logistic
regression for model building used manual backward selection procedures and included
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generalized estimating equations to account for clustering by site. Variables with p <0.05
were retained. It was anticipated that several variables would be highly correlated (e.g.,
medication dose and duration); therefore, assessment of collinearity using rank-order
Spearman correlations (rs) was included in the modeling strategy. All analyses were
conducted using Stata version 13 (Stata LP, College Station, TX).
Results
Of 2449 enrolled subjects from the RESTORE study cohort, 1170 subjects (48%)
were excluded due to receiving <5 consecutive days of opioid exposure (n=767),
incomplete sedative weaning by Day 28 (n=309), transfer (n=19) and death or redirection
of care (n=75). Of the 1279 remaining subjects, an additional 122 subjects (10%) were
excluded because they did not have any WAT-1 assessments, leaving 1157 subjects for
this analysis.
IWS was observed in 544 subjects (47%) distributed across 31 sites, although
there was a wide range in IWS rates per site (range 20%-80%). The intraclass correlation
coefficient (ICC) of IWS was 0.051 (95% CI 0.026-0.142) after adjusting for age group,
severity of illness (i.e., Pediatric Risk of Mortality [PRISM] III-12 score) and baseline
functional status (i.e., Pediatric Overall Performance Category [POPC] score). Subjects
with IWS were younger and more likely to have pre-existing cognitive and functional
impairment (Table 4-1). There was no difference in the proportion of subjects with IWS
between the control and intervention arms.
Patient-level variables: Dose and duration of both opioid and benzodiazepine
therapy were greater among subjects with IWS (Table 4-2). There was no difference in
the incidence of IWS based on primary opioid or benzodiazepine agent used for sedation.
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Opioid tolerance occurred more often in subjects with IWS. There were significant agerelated differences in both mean daily opioid and benzodiazepine dose (p<0.001 for
each), with infants less than six months of age and children over six years receiving lower
doses per kilogram regardless of IWS outcome (Figure 4-1). Age-related differences
were not observed in sedative duration (p=0.20).
Process-level variables: Patients with IWS tended to receive more classes of
sedative medications prior to the start of weaning (Table 4-2) and were more likely to be
inconsistently weaned (43% versus 26%, p≤0.001). Preweaning SBS assessment
compliance was comparable between IWS and non-IWS subjects [median (interquartile
range [IQR]): 86% (63-100) versus 80% (60-100); p=0.66].
System-level variables: Few PICU characteristics were significantly correlated
with the rate of IWS per site (Table 4-3). Median NEMS scores were 27 (IQR 27-34)
among subjects with IWS and 27 (IQR 27-33) in non-IWS subjects (p=0.07). Nurse to
patient staffing ratios were moderately correlated with the rate of IWS, suggesting higher
rates of IWS in PICUs with a greater proportion of one nurse to one patient assignments.
Regardless of IWS outcome, lower cumulative opioid doses were administered to patients
treated in PICUs with a greater proportion of one-to-one assignments compared to sites
with a lower frequency of high staffing ratios, even after adjusting for average patient
age, severity of illness, nursing workload and number of annual PICU admissions
(p<0.001).
Collinear variables: Among the preweaning medication variables, cumulative
opioid dose was strongly correlated with mean (rs=0.93, p<0.001) and peak (rs=0.90,
p<0.001) daily opioid doses and with duration of sedative exposure (rs=0.93, p<0.001).
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Benzodiazepine variables showed similar relationships. Baseline PCPC and POPC scores
were also strongly correlated (rs=0.89, p<0.001). In order to build a parsimonious and
valid model, we restricted consideration to preweaning duration of sedative exposure,
preweaning mean daily opioid dose and pre-existing cognitive impairment in
multivariable modeling.
Multivariable modeling: The multivariable prediction model identified variables
at the patient-, process- and system-levels with significant associations with IWS (Table
4-4). Each additional day of sedative exposure increased a subject’s odds of experiencing
IWS. Subjects under six months of age had the highest odds of experiencing IWS
compared to the oldest age group. Pre-existing cognitive impairment nearly doubled the
odds of IWS. Process- and system-level risk factors included receiving additional
sedative medications beyond an opioid and benzodiazepine, higher preweaning NEMS
scores and more one-to-one nurse staffing. The c-statistic for the model including only
variables with individual patient-level data was 0.63 (95% CI 0.60-0.66), which slightly
improved to 0.65 (95% CI 0.62-0.68) with the addition of the system-level variable.
Although a greater number of subjects with IWS developed tolerance compared to the
non-IWS group, that variable did not add to the predictive ability of the multivariable
model after adjusting for medication characteristics, such as duration of sedative
exposure.
Discussion
This study is the largest analysis of risk factors for IWS to date and the first to
characterize contextual influences at the system level. In addition to confirming
previously observed associations among dose and duration of sedative therapy and
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IWS,2,5,7,11,13,14,34 we have provided new evidence for risk factors related to age, preexisting cognitive impairment and nursing workload. The risk factors identified in this
study could inform future practice in sedation management.
Infants under six months of age had the highest risk of experiencing IWS relative
to other age groups. Previous studies have either been limited to specific age groups2,5,7,11
or were underpowered to show an association between age and IWS.8,12,34 Altered
pharmacokinetic profiles for sedative medications administered to neonates and infants
are related to immature enzymatic pathways.35 Morphine clearance is lower in infants
under six months regardless of hepatic or renal function, resulting in higher serum
concentrations and longer half-lives.36 Midazolam exhibits similar patterns of agedependent reductions in metabolism.37 Our results show lower preweaning mean daily
doses for both opioids and benzodiazepines among infants under six months, suggesting
that adequate sedation was achieved at lower doses. The extended bioavailability of
sedative medications in these patients may translate into prolonged receptor occupancy,
which has been implicated as a mechanism for tolerance and physical dependence.38,39
Despite the probable physiologic basis for these findings, it is possible that the observed
differences in IWS risk based on age are an artifact of the measurement approach: our
assessment tool (i.e., the WAT-1) demonstrated age-related variations in IWS symptom
presentation during initial validation.4,9 Additional research in all age groups with
measurement of plasma medication levels and/or clearance is recommended for further
exploration.
The etiology of our subjects’ pre-existing cognitive impairment is unknown.
There is growing evidence for altered neurotransmitter function in the brains of children
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with neurodevelopmental disorders causing cognitive impairments, including aberrant γaminobutyric acid (GABA) signaling40 and differing levels of endogenous opioid
production.44 Prolonged sedative administration may exacerbate existing imbalances in
inhibitory and excitatory neurotransmission in these children, with unknown
consequences when medication administration ceases. Our data suggest an increased risk
for IWS in children with pre-existing cognitive impairment, which may or may not be
related to neurochemically-based differences in medication response. The role of preexisting cognitive impairment is especially challenging to interpret given the frequent
exclusion of children with neurologic disorders from studies of IWS.3,8,13,19 The
performance of the WAT-1 in discriminating between symptoms of IWS and behavioral
manifestations of cognitive impairment is also relatively unknown, although cognitively
impaired children were in the validation sample.9 As long as sedation management for
children with cognitive impairments continues to rely on opioid and benzodiazepine
therapy, the potential risk for additional iatrogenic injury in this sub-population requires
investigation.
The contribution of severity of illness to patient risk for IWS is still unclear:
although neither PRISM III-12 scores nor preweaning number of organ systems in failure
were retained as predictors, NEMS scores are calculated from several items related to a
patient’s criticality.33 The PRISM III-12 only captures severity of illness at admission and
may not account for changes over the course of the PICU stay, reflected in its poorer
performance in predicting mortality for patients with PICU stays over six days.42 There
were too few renal and hepatic failure events for their contribution to IWS to be fully
examined. Systemic inflammation and cytokine release associated with critical illness
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have been found to decrease cytochrome P450 enzyme activity and midazolam
clearance,43 thereby increasing plasma drug levels and suggesting a possible physiologic
explanation for increased risk for IWS among sicker patients.44 However, the
pharmacodynamic effect of these changes is unknown.
Though criticality may have contributed to higher NEMS scores and their
association with IWS, the potential effects of nursing workload should also be
acknowledged. The use of system-level data makes it impossible to know the frequency
or degree to which individual patients with IWS experienced either conditions of greater
nursing workload or high nurse staffing ratios. However, higher nursing workload has
been associated with more adverse patient outcomes, such as mortality.45 There may be a
critical point at which high nursing workload increases the likelihood of adverse events.46
In contrast, allocating a greater proportion of nurse staffing to one-to-one patient
assignments is generally associated with lower risk of complications.47 The observed
increase in IWS rates with more frequent one-to-one nurse staffing may reflect an
ascertainment bias rather than a true effect on IWS risk; units where more nurses spent
their entire shift with one patient may have more successfully identified early signs and
symptoms of IWS. The observation that units reporting more frequent one-to-one
assignments also tended to administer lower cumulative doses of opioids may add
support to this hypothesis. That is, with nurses spending more of their time at the bedside,
patients were adequately sedated at lower medication doses. These interpretations should
be viewed with caution pending prospective exploration with patient-level data.
This model’s predictive performance was lower than expected, but this finding is
consistent with results from a previous study testing peak benzodiazepine dose as a risk
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factor for IWS (AUC 0.67, 95% CI not reported).34 A different multivariate predictive
model of IWS had better performance (AUC 0.83, 95% CI 0.75-0.92),10 but neither study
corrected for model overfitting and minimal data on validity were provided. Thus, our
ability to accurately predict the outcome of IWS based on clinical factors is still
unknown, and this study is the first to suggest that system-level variables may also have
an effect on IWS outcome. Currently available assessment tools were designed to
measure both opioid- and benzodiazepine-related IWS.9,25 The maximal sensitivity and
specificity of predictive models based on either instrument may be limited by different
risk profiles for each phenomenon.
This secondary analysis has limitations. First, WAT-1 assessments were not
completed in all patients with ≥5 days of sedative exposure. It is possible that restricting
analysis to the subset of patients with WAT-1 scores introduced selection bias, and the
results of this analysis are not generalizable to patients with <5 days of sedative exposure.
The outcome definition of two WAT-1 scores ≥3 has not been used previously, though it
is based on well-established cutoffs.4,9 We considered this definition to be a conservative
approach to quantifying IWS and reducing potential false positives from unrelated
conditions. Subjects with only one WAT-1 ≥3 were assigned to the non-IWS group, but
any resulting misclassification would be expected to bias the results toward the null.
Finally, while this study identified associations between IWS and several risk factors, it
did not provide causal evidence. Additional mechanistic studies are needed. The
proposed model should be validated using an independent dataset, particularly for
system-level factors collected for individual patients.
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In conclusion, IWS is a common complication among pediatric patients
recovering from critical illness. We explored the relative contributions of a number of
IWS risk factors aside from sedative dose and duration, which offer several avenues for
future investigation. Predictive modeling suggests that younger patients and those with
pre-existing cognitive impairments are at increased risk for IWS, along with patients who
experience higher mean daily opioid doses, longer exposure periods or receive more
classes of sedative medications. Inclusion of additional process and system factors
provided a novel contribution to the literature. With further prospective validation, the
identified risk factors could be used to inform individualized approaches to sedation
practice in these critically ill patients, including IWS risk assessments. 	
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Figures and Tables
Figure 4-1. Mean daily sedation dose preweaning according to age category and IWS
status
A.	
  Opioid	
  dose	
  

B.	
  Benzodiazepine	
  dose	
  

Note: Box plots present median (IQR) for each dose by age category, with outlying values (two
outliers excluded from mean daily opioid dose preweaning plot)
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Table 4-1. Demographic and clinical characteristics of study sample according to IWS
status
Characteristicsa
Age at PICU admission
Median (IQR) – years
2 weeks to 6 months
6 months to 1.99 years
2.00 to 5.99 years
6.00 to 17.99 years
Female
Non-Hispanic white, n/total n (%)
Cognitive impairment (baseline PCPC >1)b
Functional impairment (baseline POPC >1)b
PRISM III-12 score
Risk of mortality based on PRISM III-12 score, %
Organ dysfunction preweaning
Cardiovascular
Neurological
Hematological
Hepatic
Renal
No. of failed organ systems preweaning
Preweaning ECMO support
RESTORE intervention

IWS
(n=544)

Non-IWS
(n=613)

P Value

1.1 (0.3-4.4)
207 (38)
133 (24)
96 (18)
108 (20)
239 (44)
292/542 (54)
134 (25)
157 (29)
7 (3-12)
3.8 (1.0-11.7)

1.6 (0.3-6.6)
197 (32)
141 (23)
108 (18)
167 (27)
282 (46)
287/607 (47)
110 (18)
137 (22)
6 (3-11)
2.9 (1.0-9.5)

0.01
0.06

0.50
0.05
0.003
0.01
0.26
0.14

259 (48)
254 (47)
107 (20)
91 (17)
36 (7)
2 (1-3)
11 (2)
315 (58)

273 (45)
273 (45)
97 (16)
93 (15)
29 (5)
2 (1-3)
6 (1)
345 (56)

0.25
0.60
0.12
0.44
0.17
0.11
0.08
0.76

Abbreviations: ECMO – extracorporeal membrane oxygenation; IQR – interquartile range; IWS –
iatrogenic withdrawal syndrome; PCPC – Pediatric Cerebral Performance Category; PICU –
pediatric intensive care unit; POPC – Pediatric Overall Performance Category; PRISM III-12 –
Pediatric Risk of Mortality III score from first 12 hours in the PICU
a
Data are median (interquartile range) or number (%) unless otherwise specified
b
PCPC and POPC scores range from 1 to 6, with higher categories indicating greater impairment
(Fiser et al., 1992)48
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Table 4-2. Preweaning medication characteristics according to IWS status
Characteristicsa
Primary opioid preweaning
Morphine
Fentanyl
Hydromorphone or remifentanil
Primary benzodiazepine preweaning
Midazolam
Lorazepam
None
Opioid exposure preweaningb – in mg/kg
Mean daily dose
Peak daily dose
Cumulative dose
Benzodiazepine exposure preweaningb – in mg/kg
Mean daily dose
Peak daily dose
Cumulative dose
No. days of sedation exposure (opioid and/or
benzodiazepine)
Tolerance
Doubling of Day 2 opioid dose preweaning
No. of sedative classes received preweaning
<3
≤3

IWS
(n=544)

Non-IWS
(n=613)

P Value

223 (41)
321 (59)
0 (0)

259 (42)
351 (57)
3 (0.5)

481 (88)
60 (11)
3 (0.6)

515 (84)
94 (15)
4 (0.7)

2.9 (1.8-4.5)
4.5 (2.8-7.7)
19.1 (11.1-34.1)

2.6 (1.4-4.0)
3.9 (2.2-6.3)
15.7 (8.1-26.9)

<0.001
<0.001
<0.001

2.5 (1.4-4.2)
3.8 (2.3-7.1)
16.0 (8.5-31.5)
6 (5-8)

2.1 (1.1-3.7)
3.2 (1.8-6.4)
12.3 (6.6-25.2)
6 (5-7)

0.001
0.001
<0.001
<0.001

157 (29)

130 (21)

0.004

3 (2-4)
228 (42)
316 (58)

3 (2-3)
298 (49)
315 (51)

0.03
0.01

0.68

0.29

Abbreviations: IWS – iatrogenic withdrawal syndrome
a
Data are median (interquartile range) or number (%) unless otherwise specified
b
For group comparisons, continuous opioid and benzodiazepine dose variables were logtransformed to approximately normalize the variables
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Table 4-3. System-level characteristics of study sample and associations with sitespecific IWS rate
Continuous characteristics
PICU beds
Mean daily census
Annual admissions
No. PICU attending physicians
No. PICU nurses
Percent staffing that is 1 nurse:1 patient
Percent with BSNc
Binary characteristics
Medical management: Open PICU
ANCC Magnet Recognition®
Professional advancement program for nurses
Unit-based pharmacist participates in rounds

Overalla
(n = 31)
22 (16-29)
15 (11-19)
1116 (792-1827)
9 (7-10)
69 (47-97)
30 (20-50)
80 (74-90)
Sites with
characteristic
N
Rated
20
49 (3)
15
45 (3)
24
46 (3)
26
48 (3)

Correlationb
-0.18
-0.05
0.07
-0.10
0.04
0.34
-0.27
Sites without
characteristic
N
Rated
11
42 (4)
16
49 (4)
7
51 (7)
5
40 (11)

P value
0.35
0.81
0.70
0.59
0.82
0.06
0.18
P value
0.26
0.46
0.46
0.30

Abbreviations: ANCC – American Nurses Credentialing Center; BSN – Bachelor’s of Science in
Nursing; IQR – interquartile range; IWS – iatrogenic withdrawal syndrome; PICU – pediatric
intensive care unit; SBS – State Behavior Scale
a
Reported values are median (IQR)
b
Pearson’s correlations were calculated using analytic weights based on the inverse variance of
the rate of IWS by site for continuous predictors
c
Calculated correlation based on data from 29 sites
d
Reported values are mean (SE) proportion of subjects with IWS weighted by the inverse
variance of the rate of IWS by site
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Table 4-4. Predictive models of IWS
Predictor Variables
Patient-level
Age category
2 weeks to 6 months
6 months to 1.99 years
2.00 to 5.99 years
6.00 to 17.99 years
Cognitive impairment (baseline PCPC >1)
Duration of sedative exposure preweaning
Mean daily opioid dose preweaninga

Variables collected by
subject only
Adjusted ORs
P value
(95% CI)

Variables collected by
subject and by PICU
Adjusted ORs
P value
(95% CI)

2.63 (1.65-4.21)
1.62 (1.08-2.43)
1.32 (0.89-1.96)
Ref
1.87 (1.34-2.59)
1.07 (1.01-1.13)
1.25 (1.00-1.57)

<0.001
0.02
0.16
-<0.001
0.03
0.053

2.73 (1.69-4.42)
1.55 (1.03-2.34)
1.20 (0.82-1.77)
Ref
1.98 (1.41-2.78)
1.07 (1.00-1.14)
1.39 (1.16-1.67)

<0.001
0.04
0.34
-<0.001
0.046
<0.001

Process-level
No. of preweaning sedative classes ≥ 3

1.34 (1.01-1.79)

0.045

1.39 (1.04-1.87)

0.03

System-level
Median preweaning NEMS scoreb
Pct. of staffing 1 RN: 1 patientc

1.62 (1.12-2.34)
--

0.01
--

1.68 (1.18-2.40)
1.15 (1.05-1.25)

0.004
0.002

Abbreviations: NEMS – Nine Equivalents of nursing Manpower use Score; OR – odds ratio;
PCPC – Pediatric Cerebral Performance Category; RN – registered nurse
a
Odds ratio reported for change from 25th to 75th percentile of log-transformed mean daily opioid
dose
b
Odds ratio reported for a 10-unit change in NEMS score
c
Odds ratio reported for a 10% change in value
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Supplemental Methods
Variables and measures: Medication data included cumulative, mean, and peak
daily opioid dosage (in morphine equivalents per kg of body weight), cumulative, mean,
and peak daily benzodiazepine dosage (in midazolam equivalents per kg of body weight),
and administration of any other sedative medications (e.g., chloral hydrate, clonidine,
dexmedetomidine, ketamine, pentobarbital, phenobarbital, and propofol), all collected to
the start of opioid weaning. Daily and cumulative sedative medication doses were
compared using standard equivalencies.1 Specifically, morphine equivalent conversion
factors to equal 1 mg morphine sulfate were as follows: 15 µg remifentanil; 15 µg
fentanyl; 0.15 mg hydromorphone; and 0.3 mg methadone. Midazolam equivalent
conversion factors to equal 1 mg midazolam were: 0.2 mg clonazepam; 0.3 mg
lorazepam; and 2 mg diazepam. A composite variable for duration of sedation was
created, reflecting days where either opioids or benzodiazepines were administered in the
preweaning period. The start of opioid weaning was reported by the clinician and verified
or reassigned according to a standard algorithm. Tolerance to opioids was defined as a
doubling of the Day 2 opioid dose prior to the start of weaning. An inconsistent pattern of
weaning was assigned to subjects with a course of weaning that included ≥20% increases
in total daily opioid doses at any time after the start of opioid weaning.
Patient-level demographic and clinical data included age, gender, race/ethnicity,
severity of illness and mortality risk (Pediatric Risk of Mortality (PRISM) III-12),2 and
need for ECMO in the preweaning period. Subjects were considered to have a preexisting cognitive or functional impairment if their Pediatric Cerebral Performance
Category (PCPC) and Pediatric Overall Performance Category (POPC)3 scores were >1,
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respectively. Each subject was evaluated for the presence of acute organ dysfunction
prior to the start of opioid weaning based on daily lab values and other clinical data.4 All
RESTORE subjects had respiratory dysfunction. The number of organ systems in failure
was summed for the preweaning period.
Process-level variables included RESTORE group assignment and the number of
sedative medication classes administered (i.e., opioid, benzodiazepine, alpha-2-agonist,
ketamine, barbiturate, propofol, and chloral hydrate). Compliance with sedation
assessments during the pre-weaning period was a continuous variable based on daily
assessment of a child’s level of sedation using the State Behavior Scale.5 This analysis
averaged daily compliance over the preweaning period, yielding a percent compliance for
each subject.
Items drawn from the pre-randomization organizational assessments included:
hospital accreditation status with the American Nurses Credentialing Center (i.e., Magnet
Recognition® status) and availability of a professional advancement program for nurses;
PICU characteristics, such as unit-type (i.e., open versus closed), bed capacity, budgeted
census, and number of admissions in the preceding year; and staffing characteristics, such
as number of attending physicians, fellows, and registered nurses, and typical nurse-topatient ratios.
Power calculation: A total of 34 potential predictors variables at the patient-,
process- and system-level were identified for evaluation in this secondary analysis (Table
E1). Therefore, approximately 340 events were needed. Assuming an incidence rate of
approximately 30% for IWS in the study population, logistic regression of the binary
response variable (i.e., IWS versus no IWS) on continuous, normally distributed
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explanatory variables with an inflated sample size of approximately 1160 observations
was found to achieve 80% power at a 0.05 significance level to detect an odds ratio of
1.7. The estimated sample size was inflated to account for intra-cluster correlations due to
the cluster-randomized design of the parent study. Sample size calculations were based
on a small effect size (R2 = 0.08) from previous studies6 to produce conservative
estimates, and it was anticipated that the study would be adequately powered even if
some patients were excluded.
Model diagnostics: Preliminary model building was completed, and automated
stepwise regression with bootstrapping was used to check manual variable selection.
Related models were compared using Aikake information criterion (AIC) and samplesize corrected Bayesian information criterion (BIC) values. These analyses were
completed using Mplus version 7 (Muthén & Muthén, Los Angeles, CA). After
determining the final model, model assumptions and fit were checked using c-statistics,
receiver operating characteristic (ROC) and calibration curves. The robustness of the
findings was further assessed using k-fold cross-validation for model calibration and
bootstrapping procedures to obtain bias-adjusted confidence intervals.

123

Supplemental Table
Table 4-5. Predictor variables of interest
Variable
Patient-Level
Age
Gender
Race/Ethnicity
Pre-existing cognitive disability
Pre-existing physical disability
Severity of illness (PRISM III-12 score)
Meets organ dysfunction criteria
Extracorporeal support required during
hospitalization preweaning
Tolerance to opioids
Peak, total and cumulative [preweaning]
opioid exposure and duration
Peak, total and cumulative [preweaning]
benzodiazepine exposure and duration
Process-Level
Number of classes of sedative agents
Sedation assessment compliance
Inconsistent pattern of weaning
RESTORE intervention
System-Level
Nursing workload (NEMS score)
Unit-based pharmacist participation in
daily rounds
Total number of PICU beds
Mean PICU daily census
Annual PICU admissions
Number of PICU attending physicians
Number of PICU nurses
Proportion of staffing with 1 nurse:1
patient
Proportion of BSN-prepared nurses
Professional advancement program for
nurses
ANCC Magnet Recognition
Medical management: Open PICU

Type

Timing of Measurement

Continuous
Binary
Binary [Non-Hispanic
White/ Minority]
Binary
Binary
Continuous
Categorical
Binary

Admission value by
subject

Preweaning summary by
subject

Binary
Continuous
Continuous

Categorical
Continuous
Binary
Binary

Preweaning summary by
subject

Continuous

Preweaning summary by
subject
By PICU

Binary
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Binary
Binary
Binary
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CHAPTER 5
DISCUSSION AND CONCLUSION
Sedation management in the pediatric intensive care unit (PICU) is a complex
process that requires the consideration of many factors to proceed optimally; there are
multiple decision points that could potentially set a patient on the path to experiencing
iatrogenic withdrawal syndrome (IWS). Sedative medications elicit variable patient
responses, so patients are prescribed medications at pharmacokinetically and
pharmacodynamically appropriate doses to achieve the desired effects (Johnson et al.,
2012). Clinical practice has gradually incorporated routine evaluation of pain and level of
sedation (Playfor et al., 2006), which has improved patient comfort during the critical
phase of illness. To a lesser extent, clinicians are increasingly aware of the potential for
medication tolerance, which is typically addressed by increasing sedative doses to
maintain therapeutic effectiveness (Anand et al., 2010). This careful focus on patient
comfort must be balanced against other clinical priorities during recovery, such as
endotracheal extubation. The point at which concurrent ventilator and sedation weaning
begins generates conflicting goals of preventing respiratory depression and promoting
spontaneous breathing while avoiding patient discomfort (Brinker, 2004). Optimal
sedation arguably requires a smooth transition from acute illness to recovery, especially
when poorly executed sedation weaning leads to uncomfortable complications, like IWS,
which are profoundly distressing for patients and families. Unfortunately, little attention
has been paid to characterization of the crucial period of sedative weaning and the events
that follow. This dissertation study contributed to current knowledge regarding pediatric
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sedation management by exploring the relationship between weaning and IWS outcomes,
and by identifying additional contributors to the development of IWS.
Summary and Overall Goals
The three papers presented in this dissertation study collectively accomplished the
following objectives: 1) exploring the available literature on iatrogenic withdrawal
syndrome (IWS) to identify known and hypothesized risk factors for IWS in pediatric
patients recovering from critical illness, 2) generating and characterizing patterns of
sedation weaning to examine their association with the outcome of IWS, and 3)
constructing a predictive model of patient risk for IWS to suggest improvements in future
care of patients being weaned from sedation. The conceptual model created in the first
paper (Chapter 2) elucidated relationships that were further explored in the remaining
analyses (Chapters 3 and 4) and provided a framework for interpreting their findings. For
example, tolerance and weaning were two identified concepts that were intricately related
to IWS but which required more empirical evaluation. The description of usual clinical
practice for sedative weaning in drug tolerant children (Chapter 3) tested operational
definitions that performed well, warranting their inclusion in the exploratory modeling of
IWS risk completed in Chapter 4.
Major Findings: Tolerance
Physiologically, tolerance is an adaptive process whereby changes in receptor
number and composition, uncoupling of secondary messenger systems, and increased
release of various neuroactive substances are hypothesized to cause decreased therapeutic
effectiveness of medications (Anand et al., 2010; Barr et al., 2011; Vinkers & Olivier,
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2012). Tolerance is neither necessary nor sufficient for the development of physical
dependence and subsequent IWS (Vinkers & Olivier, 2012), although tolerance and IWS
may share certain predisposing factors, including sedative duration. They are distinct
phenomena that occur during and after treatment, respectively, and have different
implications for clinical management. Tolerance is undesirable since it interferes with the
attainment of optimal sedation, and investigations of predictors for tolerance (Anand et
al., 2013) may be valuable for increasing the efficiency of sedation practice. When
managed through appropriate dose escalation in acute illness and gradual weaning during
recovery, tolerance is not directly harmful to patients. It is only when tolerance leads to
physical dependence and subsequent IWS that added patient discomfort, anxiety for
families, and increased costs of care manifest (Franck et al., 1998; Johnson et al., 2012;
Sorce, 2005). Thus, for the purposes of this investigation of risk factors for IWS,
tolerance is only relevant in the subpopulation of patients for whom it develops prior to
IWS.
Unfortunately, quantifying tolerance remains challenging. Since the exact cellular
mechanisms underlying medication tolerance are still under investigation, there are no
biological markers signaling its development. Providers have traditionally relied on dose
escalation and decreased effectiveness of sedative medications as clinical indicators of
tolerance (Anand et al., 2010). Opioid dose escalation is not specific to tolerance, as it
could be related to the increased need for post-surgical analgesia or sub-optimal initial
doses. The revised operational definition of tolerance that was used in the second and
third papers accounted for this lack of specificity by comparing later opioid doses to the
Day 2 dose, rather than the first 24 hours’ dose as in previous publications (Anand et al.,
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2013). Yet over 20% of subjects without IWS (based on WAT-1 scores) still met criteria
for tolerance in both studies, further illustrating that tolerance may be insufficient to
trigger physical dependence and IWS in the absence of other risk factors. This result may
also be indicative of a continued lack of specificity in the revised definition of tolerance.
More accurate clinically-based definitions of tolerance require a subjective assessment of
the point at which adequate sedation was achieved in order to determine when therapeutic
effectiveness starts to diminish, which may not be feasible for patients along varying
illness trajectories and which poses problems for generalizability and reproducibility.
These are all important considerations that may help explain why tolerance was not
retained as a significant predictor in the final multivariable model of IWS risk.
In the conceptual model from Chapter 2, the various risk factors for IWS were
classified as either tolerance- or non-tolerance-related. From a theoretical standpoint, it is
still reasonable to consider tolerance as a potential contributor to IWS risk for certain
patients, since tolerant patients appear to experience longer durations of sedative
exposure. Alternatively, evaluating the sub-population of patients who develop tolerance
but not physical dependence may prove to be advantageous, if protective factors could be
identified that prevent the development of IWS. In either case, further work in this area
may need to wait for more precise measures of tolerance to be developed, separating it
from the other clinical influences driving dose escalation in the context of critical illness.
Major Findings: Weaning
Sedative weaning has received limited attention in the pediatric literature, except
in studies testing the use of pharmacologic therapies to facilitate faster weaning without
precipitating IWS (Bowens et al., 2011; Jeffries, McGloin, Pitfield, & Carr, 2012;
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Johnson et al., 2010; Meyer & Berens, 2001; Siddappa et al., 2003; Tobias, 2006). To
date, published reports on sedation weaning have relied on quantifying dose reductions as
percentages of the original dose (Ducharme et al., 2005), often assuming that weaning
occurs as a linear decrease in dose over time at a rate determined by the healthcare
provider. Only one recent descriptive study described daily opioid tapering that included
increases in dose after the start of weaning, which occurred in 88% (n=22) of patients
(Fisher et al., 2013). The portion of this dissertation study investigating patterns of
weaning demonstrated that nearly half of patients experienced inconsistent patterns of
weaning, which were associated with lower average percent drops in opioid dose and a
higher incidence of IWS. Both prospective studies described in this dissertation further
showed that the rate of dose reduction is not a key determinant of either weaning
trajectory or development of IWS.
It was somewhat unexpected that predictors of inconsistent weaning patterns
could not be identified from preweaning variables. However, on further scrutiny this
difference in findings between the second and third papers – that is, that clinical variables
may predict the outcome of IWS but not weaning patterns – highlights the fact that the
etiology of IWS risk is multifactorial. These results also suggest that variations in
sedative weaning are better explained by clinician or system factors than by inherent
differences in severity of illness or sedative responsiveness in individual patients.
Although additional work should prospectively examine this hypothesis, if confirmed it
reinforces the need to critically reexamine the process in which sedation-related decisions
are made in the PICU.
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Major Findings: Patient-Level Risk Factors
The systematic review (Chapter 2) identified an area of disagreement in the
current literature on patient-level risk factors for IWS: the evidence was inconsistent
regarding the contribution of age to IWS risk, with some studies suggesting associations
with either younger or older age. The results described in Chapter 4 provide evidence to
resolve this question, since younger children had the highest incidence of IWS of the four
age groups examined. The high rate of IWS in young infants was primarily interpreted in
the context of developmental changes in the pharmacokinetics of sedative drugs; namely,
that the CYP3A4 and UGT2B7 enzymes are differentially expressed and have low
activity during the first days to weeks of life (de Wildt, de Hoog, Vinks, van der Giesen,
& van den Anker, 2003; Knibbe et al., 2009; McRorie, Lynn, Nespeca, Opheim, &
Slattery, 1992; Salem, Johnson, Abduljalil, Tucker, & Rostami-Hodjegan, 2014). Rates
of drug metabolism and clearance change from birth to 6 or 12 months (Anderson &
Larsson, 2011; Knibbe et al., 2009), depending on the individual patient’s physiology and
the medication under examination (Kearns et al., 2003).
The lower mean daily opioid and benzodiazepine doses observed in patients under
six months suggest that the ontogeny of drug metabolism in these patients was taken into
account in dosing during the preweaning period. Since receiving lower doses of sedative
medications still did not result in a lower incidence of IWS in this patient group, perhaps
a greater awareness among clinicians of the potential effects of delayed clearance on the
development of physical dependence is warranted. Specifically, daily dose reductions
(Anand et al., 2010; Galinkin & Koh, 2014) may be misaligned with extended hepatic
clearance times in young infants, resulting in dramatic changes in plasma serum
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concentrations during weaning. More gradual weaning may be necessary in the youngest
group of patients to prevent the development of IWS. There were no age-related
differences in the patterns of weaning described in Chapter 3, which could mean that
signs of IWS are not addressed with rescue medications as often in young infants. A
simpler explanation is that young infants are weaned in a similar manner to older
patients, suggesting an opportunity both to try more individualized sedation or weaning
approaches in infants under six months and to improve the management of IWS
symptoms as they occur in these patients.
Although the literature review identified several anecdotal reports of more
frequent IWS in children with pre-existing disorders or hypoxemic brain injuries, it was
surprising that the study in Chapter 4 was able to show a relationship between preexisting cognitive impairment and IWS. The Pediatric Cerebral Performance Category
(PCPC) is a gross measure of cognitive impairment in children, which has been
correlated with risk of mortality, PICU length of stay, discharge care needs and long-term
developmental outcomes (Fiser et al., 2000; Fiser, 1992). However, PCPC scores have
not been previously used to predict more short-term outcomes or complications that are
contingent upon several aspects of clinical care. In the case of IWS, pre-existing
cognitive impairment as a risk factor for IWS may be too granular to drive real changes
in sedation management without further investigation. As described in Chapter 4,
neurochemical differences in excitatory and inhibitory transmission may explain this
finding, but additional pre-clinical work is needed to explore the pharmacodynamics of
sedative medication activity in neurologically impaired brains.
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As a general observation, the use of sedative medications in children with
cognitive and neurological impairments is relatively poorly characterized. For example,
only recently have studies been published to counter the notion that children with Down’s
syndrome have higher opioid requirements than other critically ill children (Valkenburg
et al., 2012; Van Driest et al., 2013). This gap in the literature is problematic, given that
up to a quarter of PICU patients may have pre-existing cognitive impairments (Graham,
Dumas, O’Brien, & Burns, 2004) and that advances in medical care have led to
increasing numbers of children with technological dependence and/or chronic conditions
with neurologic components (Namachivayam et al., 2010; Odetola, Gebremariam, &
Davis, 2010). Up to this point, evidence has shown that sedative medications are effective
for use in children with cognitive impairments (Buck & Willson, 2008; Kilbaugh, Friess,
Raghupathi, & Huh, 2010; Valkenburg, van Dijk, de Klein, van den Anker, & Tibboel,
2010), but the results of this study suggest that more careful evaluation of the safety and
long-term effects of these medications may be needed in this population.
There is a robust body of evidence for sedative dose and duration as risk factors
for IWS (Chapter 2). The results of this dissertation unanimously confirmed the
importance of considering both variables in evaluating a patient’s probable course of
weaning and predicting risk for IWS; therefore, the inclusion of both a dose and duration
variable in the predictive model (Chapter 4) gives some measure of face validity to the
findings. In addition, though it is intuitive for clinicians that patients receiving higher
preweaning doses and/or longer durations of sedation have more difficulty with weaning,
the analysis presented in Chapter 3 was the first direct evaluation of the contributions of
preweaning sedative dose and duration to weaning outcomes. A problem in some older
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studies of IWS (Bergman et al., 1991; Dominguez et al., 2003; Fonsmark et al., 1999;
Franck et al., 1998; French & Nocera, 1994; Hughes et al., 1994; Katz et al., 1994) that
was identified and addressed in these dissertation studies, is the inclusion of medication
doses received after the start of weaning in quantifying the relationship between sedative
exposure and IWS. A few recent investigations have differentiated between pre- and
post-weaning doses and acknowledged the correlations among medication variables
(Franck et al., 2008; Franck et al., 2012). However, by highlighting this gap in previous
approaches, these methods and findings add a much-needed level of conceptual clarity to
the study of contributors to IWS in critically ill children.
Major Findings: Process-Level Risk Factors
The only process-level factor found to be a significant predictor of IWS was
number of sedative agents used in the preweaning period: subjects who received three or
more classes of sedative medications were more likely to experience IWS. The same
variable did not achieve statistical significance in the study of weaning patterns, though
inconsistently weaned patients did appear to receive more sedative agents in the
preweaning period, and receipt of additional sedative classes occurred more frequently
among inconsistently weaned patients during weaning (p<0.001). Taken together, these
findings highlight the difficulty of interpreting the relationship between multi-drug
therapy and IWS: prescription of additional sedative medications during weaning is most
indicative of attempts to manage emergent signs and symptoms of IWS, but in the
preweaning period the clinical rationale for this approach requires some speculation. It is
likely that at least some of the children who received three or more sedative agents were
difficult to sedate with traditional opioid and benzodiazepine medications. There is an
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incomplete understanding of the reasons for pharmacodynamic variation in sedative
response in critically ill children (Johnson et al., 2012; Vet, de Hoog, Tibboel, & de
Wildt, 2011), and even less about how it might translate into a predisposition for physical
dependence or difficulties with weaning. This finding is particularly perplexing to explain
given that the direction of effect was opposite that in a previously published model of
IWS risk (Ista et al., 2013), which reported seemingly protective effects for one or two
additional sedative medications (respectively, OR 0.11, 95% CI 0.28-0.42, p=0.001; OR
0.19, 95% CI 0.05-0.76, p=0.02). However, that study did not clearly describe whether
additional sedatives were administered solely in the preweaning phase and did not
distinguish between medications treating signs and symptoms of withdrawal (i.e.,
clonidine, ketamine, fentanyl) versus other sedatives (i.e., propofol). Their findings may
reflect more proactive treatment of mild symptoms of IWS during weaning, while ours
specifically address sedative needs in the preweaning period.
It is interesting that RESTORE group assignment did not appear to influence the
outcome of IWS. The primary study found that patients in the intervention group had
fewer days of opioid exposure, received fewer sedative classes (including less
methadone), and, based on sedation assessments, were more often considered to be
awake and calm during mechanical ventilation than subjects in the control group (Curley
et al., 2015). Nevertheless, IWS rates reported in the primary paper were 68% in both
study groups. This result may be a reflection of the complex nature of IWS, wherein
other determinants of a patient’s risk could offset the beneficial effects of lower
medication doses. For example, more patients less than two years of age were enrolled in
the intervention group, and their higher observed rates of IWS might have obscured the
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potentially preventive effects of the sedation protocol on the incidence of IWS.
Compliance with WAT-1 assessments was also higher in the intervention group, raising
the distinct possibility that IWS was more likely to be identified in those patients. Thus,
the results in Chapter 4 cannot be interpreted as a statement on the effectiveness of
standardized sedation protocols in preventing IWS, and it is recommended that additional
studies using IWS as the primary outcome be developed to more thoroughly evaluate this
relationship.
Major Findings: System-Level Risk Factors
A novel contribution of this dissertation was the evaluation of the effects of the
healthcare system on the outcome of IWS. As a phenomenon defined primarily by its
clinical signs and symptoms, IWS is typically described at the patient level. Many
previous investigations have been limited to single centers and could not comment on
variations across sites. However, certain authors noted process challenges (Carnevale &
Ducharme, 1997; Ducharme et al., 2005; Jin et al., 2007) which suggested elements of
sedation management that were common across institutions. The literature review
(Chapter 2) demonstrated that studies of IWS up to this point have frequently lacked
contextualization based on the unique circumstances in which sedation occurs, namely,
within complex health systems.
Systems factors were not directly evaluated in the second study, but using
baseline data from the RESTORE trial yielded findings that were potentially driven by
practice norms at each of the participating PICUs. Unmeasured influences on inconsistent
weaning may have existed, such as periods of high unit census and hospital policies
prohibiting use of continuous infusions on general floor units (Tobias, 2000). Clinicians
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sometimes perceive that gradual tapering of sedatives will delay extubation or discharge
from the PICU to the floor (Tobias, 1996, 1999), despite the fact that studies of
standardized sedation protocols including weaning (Deeter et al., 2011; Jin et al., 2007;
Keogh, Long, & Horn, 2015) have shown decreased or unchanged lengths of stay.
However, there have been no systematic investigations of the precise relationship
between sedative weaning as the primary intervention and time to extubation or
discharge, besides a study showing no difference in the success rate of methadonefacilitated weaning using a 5 or 10 day protocol (Bowens et al., 2011). Nevertheless, over
the course of the RESTORE trial, clinicians expressed a declining inclination to wean
sedative medications (Best, Wypij, & Curley, 2014), presumably in favor of rapid
discontinuation of continuous infusions. Thus, if faced with a shortage of PICU beds and
external pressure to move patients to the floor, patients who otherwise would be weaned
more slowly might be pushed into the process prematurely. This explanation is purely
speculative, and may be countered by the observation that percent decreases in opioid
dose were lower among inconsistently weaned patients.
In the final paper, both high nursing workload and greater proportions of high
nurse to patient staffing ratios were identified as contributors to IWS risk. The discussion
in Chapter 4 thoroughly explored the potential implications of these findings, which
unfortunately offer limited room for interpretation because of the lack of patient-level
data. Nurse to patient staffing ratios are often used in health policy research as an indirect
indicator of nursing workload (Carayon & Gürses, 2005; Cimiotti, Barton, Chavanu
Gorman, Sloane, & Aiken, 2014; Tubbs-Cooley et al., 2013), and higher levels of nurse
staffing are typically associated with improved quality of care and better patient
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outcomes (Numata et al., 2006). Therefore, the direction of the effect of staffing ratios on
IWS incidence contradicted the finding that higher nursing workload (based on NEMS
scores) was a risk factor for IWS. Although the most logical explanation is an effect of
ascertainment bias, there may be other relevant but unmeasured influences at sites with
higher proportions of one-to-one nurse staffing that do exert a true effect on increased
risk for IWS, such as work environment (Kelly, Kutney-Lee, Lake, & Aiken, 2013;
McHugh et al., 2013) or nursing education (Aiken et al., 2003; Egerod, 2002; Guttormson
et al., 2010; Kutney-Lee et al., 2013).
The fact that unit size and number of annual admissions were not found to have
significant relationships with IWS is not unusual. One systematic review of
organizational research in healthcare reported that more than 45% of studies investigating
the effects of the system or structure on patient outcomes yielded non-significant findings
(Hearld et al., 2008). This observation stems in part from the complexity of clinical
patient care, especially in the PICU, where a diverse set of process and system influences
can operate to varying degrees to either directly or indirectly influence patient-level
outcomes. However, previous pediatric studies have demonstrated associations between
PICU volume and patient outcomes (Tilford, Simpson, Green, Lensing, & Fiser, 2000).
The final study (Chapter 4) attempted to address this challenge by adjusting for factors at
the patient, process and system levels. It is also possible that the reported proportion of
high nurse-to-patient staffing ratios at each site was indirectly related to unit volume or
census, and therefore including the staffing variable accounted for those effects. Overall,
a few system-level variables did reach statistical significance in this analysis. Further
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exploration of systems influences on IWS might confirm these results or identify
additional system-level contributors.
Limitations
The limitations of this dissertation include the use of an unvalidated conceptual
model, difficulty in operationally defining and measuring certain variables of interest,
and potential biases in the available study sample. The conceptual model developed in the
first study was derived through a qualitative synthesis of the available literature on IWS
risk; it is possible that another author provided with the same data might have reached
different conclusions. The remaining studies in this dissertation used this framework to
guide variable selection, which may have led to erroneous assumptions about the
relationships between variables. However, the final study successfully identified
predictor variables at each level of the model, lending some support to the initial
hypothesis that influences outside of the patient ought to be considered.
As in previous studies of sedation management in the PICU, these analyses were
unable to differentiate between the effects of opioid and benzodiazepine exposure on
either weaning patterns or IWS risk. Only two studies to date have examined both opioid
and benzodiazepine patterns of weaning together (Ducharme et al., 2005; Ista et al.,
2013), in part due to the difficulty of defining the start of weaning for each individual
medication. Rather than replicating these approaches, this dissertation defined the start of
weaning relative to opioid administration, which has been more thoroughly described as a
contributor to IWS in children recovering from critical illness. This design decision may
have neglected important information that could have been gleaned from considering
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both medications together, especially since less is known about physical dependence on
benzodiazepines and appropriate weaning approaches.
Inconsistent patterns of weaning were more frequently observed among patients
with IWS compared to non-IWS patients, but ultimately this association was not explored
further in the final study (Chapter 4), in part because of the difficulty in demonstrating
causal relationships in this study design. Specifically, inconsistent weaning could not be
definitively identified as the cause of higher observed WAT-1 scores in either of the
studies including weaning pattern. Future prospective analyses could investigate the
timing of onset of IWS symptoms relative to the start of inconsistent weaning.
Compliance with standardized assessments was less than perfect in the studies
that relied upon baseline (Chapter 3) and post-randomization data (Chapter 4), making
interpretation of the results more challenging. Difficulties with compliance have been
frequently reported in the literature on sedation assessment: a recent survey noted that
although 70% of respondents worked in PICUs implementing standardized sedation
assessment tools, only 42% of clinicians actually used them to guide sedation
management (Kudchadkar, Yaster, & Punjabi, 2014). Given the recent development of
both the WAT-1 (Franck et al., 2008; Franck et al., 2012) and its Dutch counterpart, the
SOS (Ista et al., 2008; Ista et al., 2013), very little research has evaluated compliance
with withdrawal assessment, particularly over the course of a five year clinical trial.
However, published findings indicate inconsistent use in clinical practice (Jeffries et al.,
2012; Keogh et al., 2015). It is likely that non-compliance with sedation and withdrawal
assessments is at least in part related to clinician biases: patients who were perceived to
have a “smoother” sedation course may have been less likely to be assessed, if they were
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considered by clinicians to be at lower risk for IWS than patients with more complex
sedation needs. However, there was no way to directly evaluate the effects of clinician
attitudes and beliefs in the context of this secondary analysis.
Finally, as has been stated previously, the association between system-level
variables and IWS outcome could not be adequately assessed in the absence of
individually collected data for each subject. As a secondary analysis, the self-reported
site-level organizational assessment data were the only available system-level variables.
There was variation over the course of the study in terms of what data was available at
each site, and many sites simply did not have processes in place for obtaining the
requested data, particularly for nursing variables. As a result, there was more missing
data in the organizational dataset than in the larger study.
Future Directions
The most obvious contribution of this dissertation work is to suggest additional
caution in the approach to sedation management and weaning in certain groups of
critically ill children. Patients under six months of age may require an alternative strategy
of sedation titration to avoid doses that induce physical dependence and possibly different
weaning approaches to avert symptoms of IWS. However, weaning alone may be
ineffective as an approach to preventing IWS. Sedation in children with pre-existing
cognitive impairments should also be managed conservatively. The design of this
dissertation study precludes any mechanistic explanation for why these patients may have
experienced more IWS despite similar sedative doses and duration of exposure. It is
reasonable to hypothesize that these patients have altered responses to sedative
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medications due to pre-existing neurochemical differences, but additional pre-clinical and
clinical studies are needed.
Although this study was originally intended to investigate the relationship
between race/ethnicity and risk for IWS, this was not done for several practical reasons.
Documentation of race/ethnicity in the RESTORE trial was based upon the research
personnel’s impressions of the patient on admission and was not self-reported, raising
concerns about potential misclassification. The theoretical basis for including
race/ethnicity as a potential risk factor for IWS could not be substantiated; it is unknown
whether the underlying distribution of polymorphisms in genes responsible for opioid
and/or benzodiazepine metabolism would be reproduced by the available codings of
race/ethnicity without analysis of biological data from the sampled RESTORE subjects.
Adopting race/ethnicity as proxies for genetic differences in drug metabolism is no longer
a recommended approach in pharmacogenetic research (Lee, 2009). Therefore, future
studies including patient genotypes for potentially contributory genes – such as single
nucleotide polymorphisms in the mu opioid receptor (OPRM1), ATP binding cassette
transporters (ABCB1), and the cytochrome P450 family (Anand et al., 2010) – should
examine direct relationships with the outcome of IWS. Some of this work is already in
progress, with promising results (Beer et al., 2013).
This study of risk factors for IWS in pediatric patients recovering from critical
illness has provided valuable insights into current processes of sedation management in
the PICU, but it also raises a host of new questions. For example, despite efforts to
explore the system context of sedation management in the PICU, little is known about the
physical environment in which the children in these analyses were receiving sedation
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therapy and recovering from critical illness. Although gradual weaning remains the most
promising approach to reducing the incidence of IWS, there is increasing interest in
reducing noxious environmental stimuli as a means to decreasing sedative needs in
critically ill children. Families could be engaged in helping to use non-pharmacologic
measures for reducing agitation, such as music therapy, massage, and other
complementary therapies (Brinker, 2004; Stephen Playfor et al., 2006). However, the
success of such interventions is contingent upon the unique organizational dynamics of
the PICU (Burns, 2012; Thomas & Dhanani, 2010).
If the system-level variables identified in this study are examined prospectively
with patient-level data and similar relationships are observed, it may be advisable to
examine strategies for increasing resources and better allocating nursing assignments for
high-risk patients. Recent studies have suggested that inadequate nursing resources are
associated with reduced surveillance for potential changes in patient condition (Cimiotti
et al., 2014) and more instances of “missed care” (Ball, Murrells, Rafferty, Morrow, &
Griffiths, 2014). It would be interesting to probe the process of how nurses allocate their
time to sedation-related versus other care activities, how sedation assessment and
weaning are prioritized, and what additional resources could help support optimal
practice, thereby reducing nursing workload. Such an investigation could incorporate an
assessment of the quality of interprofessional dialogue surrounding sedation; relying on
Magnet status as an indicator of the quality of work environments may have been too
granular an approach in this study, and previous findings strongly suggest that
interprofessional communication regarding sedation goals influences nurses’ attitudes
toward weaning and IWS assessment (Suddaby & Josephson, 2013).
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Conclusion
This dissertation has explored and advanced knowledge regarding iatrogenic
withdrawal syndrome in children recovering from critical illness and weaning from
sedative medications. The conceptual model proposed in the first paper provided a
framework for designing and interpreting the remaining two studies, although external
validation is needed. In addition to critically examining the role of tolerance in
precipitating IWS, this dissertation has elucidated the relationship between weaning and
IWS, and provided a reproducible methodology to guide future research. Most
importantly, both classic and novel risk factors together contributed to a predictive model
of IWS risk that adjusted for variables at the levels of the patient, process and system.	
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APPENDICES
Appendix 1. Withdrawal Assessment Tool-version 1 (WAT-1)

Reference: Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the
Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric
patients. Pain. 2012;153(1):142–148.
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